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Kyle Benjamin Martin 
 
IDENTIFICATION OF ALTERED RAS SIGNALING AND INTERMEDIATE 
FILAMENT HYPERPHOSPHORYLATION IN GIANT AXONAL NEUROPATHY 
 
Giant axonal neuropathy (GAN) is a rare genetic disease that causes 
progressive damage to the nervous system. Neurons in GAN patients develop an 
abnormal organization of cytoskeletal proteins called intermediate filaments (IFs), 
which normally provide strength and support for the overall cell structure. The 
irregular IF structure in GAN patient neurons leads to a progressive loss of motor 
skills in children and subsequent death in adolescence. GAN is caused by 
reduced levels of the gigaxonin (Giga) protein. Giga functions to control the 
degradation of other cellular proteins, and the loss of Giga in GAN cells results in 
significantly elevated levels of the galectin-1 (Gal-1) protein. Gal-1 stabilizes the 
active form of the Ras signaling protein, which functions as a molecular switch to 
regulate the phosphorylation and subsequent organization of IFs. The connection 
between these pathways led us to propose that Giga regulates IF 
phosphorylation and structure by modulating Ras signaling through the 
degradation of Gal-1. Using GAN patient cells, we demonstrated that restoring 
Giga reduced Gal-1 protein levels, decreased IF phosphorylation, and 
reestablished normal IF organization. Similar effects of reduced IF 
phosphorylation and improved IF structure were also obtained in GAN cells by 
directly decreasing the protein levels of either Gal-1, or downstream Ras 
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signaling proteins. Taken together, these results demonstrate that the loss of 
Giga induces Gal-1 mediated activation of Ras signaling, thereby leading to the 
increased IF phosphorylation and abnormal IF structure observed in GAN cells. 
Identification of aberrant Ras signaling is significant because it is the first to 
specify a mechanism by which the loss of Giga leads to the development of GAN 
and provides targets for novel drug therapies for the treatment of this currently 
immedicable genetic disease. 
 
R. Mark Payne, M.D., Chair 
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CHAPTER I: INTRODUCTION 
 
Giant Axonal Neuropathy: description and clinical overview 
Giant Axonal Neuropathy (GAN) is a rare autosomal recessive disease 
characterized by early onset and progressive neurologic dysfunction in both the 
peripheral nervous system (PNS) and central nervous system (CNS). GAN 
patients are undiagnosed at birth due to the apparent lack of symptoms at this 
time. Patients demonstrate slightly delayed motor development through the first 
years of life, but they usually begin to walk in a time frame commensurate with 
their peers (1-3). As the disease progresses, however, GAN patients slowly 
develop PNS dysfunction that presents as a gait disorder around the age of two 
to five years old (3). The ambulatory ability of GAN patients slowly deteriorates 
until a walking aid is needed around the age of eight to twelve years old, and the 
neurologic dysfunction eventually progresses to a point where they become 
confined to a wheelchair in middle to late adolescence (3). Eventually, multiple 
functions of the autonomic nervous system fail in patients, thus necessitating the 
use of feeding tubes and ventilators in the advanced stages of the disease (4). 
GAN patients ultimately die of respiratory failure, usually in their second decade 
of life (5, 6). 
 Throughout the progression of the disease, motor and sensory neuron 
abnormalities are observed as most patients exhibit distal muscle weakness, 
distal sensory impairment, nystagmus, and areflexia (6-8). Other less common 
symptoms include optic atrophy, epilepsy, dysarthria, and developmental delay 
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(6, 8, 9). Upon electrophysiological examination, these symptoms were shown to 
be the result of decreased nerve conduction velocities and massively reduced 
motor and sensory nerve action potentials (9, 10). In addition to the PNS defects, 
additional tests demonstrated CNS dysfunction through irregular 
electroencephalography readings and magnetic resonance imaging of diffuse 
white matter abnormalities in these patients (2, 7, 11, 12). Further CNS 
involvement in GAN was confirmed by magnetic resonance spectroscopy, which 
showed significant demyelination and neurodegeneration in white matter as well 
as a proliferation of glial cells in both white and gray matter (13, 14). 
 These clinical findings are not inherently unique to GAN as similar 
symptoms are observed in multiple other childhood disease involving chronic 
polyneuropathy. There are two characteristics, however, that are distinctive 
features of this disease. The first is the presence of tightly curled, or sometimes 
referred to kinky, hair that is observed in most GAN patients (1-3, 7, 9, 12, 15, 
16). In each case, the tightly curled hair is observed on the head, eyelashes, and 
eyebrows, and is distinctly different from that of the parents. GAN patients have 
been observed in many different ethnic backgrounds, including Japanese, Indian, 
and European descent, with each having this remarkably curly hair (6, 17). 
Ultrastructural examination of hair samples from multiple GAN patients were 
mostly unremarkable, but revealed the presence of unusual longitudinal grooves 
throughout the hair (2, 10, 18). Although this remains an interesting finding, the 
mechanism of altered hair structure and its relevance to GAN remains unknown. 
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In addition to this unique hair phenotype, GAN patients also have a 
second distinctive characteristic of enlarged, or so-called “giant,” neuronal axons 
from which the name of the disease was derived (1). These enlarged axons 
measure 30-50 µm in diameter in sural nerve cross sections (6, 18, 19) and are 
significantly larger than the 3-6 µm diameter axons observed in unaffected 
individuals (20). Axonal enlargements are not uniform throughout the entire 
length of the neuron, however, as longitudinally dissected nerve fibers reveal 
segmental swellings with intermittent areas of normal axon diameter (1, 2, 11, 
21). The distended segments tend to be more abundant in the proximal region of 
the axon, with swellings near the axon hillock, and are less commonly found in 
distal region (18, 22). Each enlarged axonal segment is also noted as having an 
abnormally thin or completely absent myelin sheath (11, 12, 17, 19). In addition 
to the irregular neuronal structure, patient biopsies also reveal reduced nerve 
fiber populations, thus indicating axonal loss and neurodegeneration (1, 17, 21). 
This phenotype of giant axons, thin myelin sheaths, and neurodegeneration is 
observed throughout the entire nervous system, with similar observations noted 
in the peripheral nerves, spinal cord, and cerebral cortex (18, 23). 
 Ultrastructural analysis of the enlarged axonal segments revealed the 
presence of densely packed and disorganized neuronal intermediate filaments, 
termed neurofilaments (1, 7, 12, 21). Neurofilaments, along with actin and 
microtubules, comprise the cytoskeletal structure needed to maintain neuron 
organization and function. The abnormal accumulation of neurofilaments, 
however, impedes GAN patient neuronal function by occupying all the axonal 
3 
 
space and displacing other organelles (6, 17, 23). Mitochondria and microtubules 
are particularly affected, as they are excluded from the central neurofilament 
mass and found only sparingly in the periphery of each enlarged axonal segment 
(1, 19, 24, 25). Conversely, the intermittent narrow portions of the axon contain 
only microtubules and mitochondria and are devoid of neurofilaments (1, 22). 
This interesting observation demonstrates that the accumulation of 
neurofilaments is responsible for the giant axons observed in patients, and 
prompted GAN to be classified as a disease of the intermediate filaments.  
 
Function and dynamics of intermediate filaments 
 Intermediate filaments (IFs) were initially described nearly a half century 
ago and the name was derived from their diameter (10 nm) being intermediate in 
size compared to that of microfilaments (7 nm) and microtubules (24 nm) (26). In 
contrast to microfilaments and microtubules, which are composed of highly 
conserved globular actin and tubulin proteins, respectively, IFs are constructed 
from a highly divergent family of filamentous proteins. Each member of the IF 
family contains a prototypical three domain structure that includes a non-α-helical 
amino-terminal head domain, a central α-helical rod domain, and a non-α-helical 
carboxyl-terminal tail domain (27, 28). Although the central rod domain is largely 
conserved between IF proteins, high variability in both the head and tail domains 
has led to the identification of at least 67 different IF proteins that share as little 
as 20% sequence identity (27). This large group of divergent proteins was 
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eventually classified into five distinct types based on sequence similarity, 
assembly properties, and expression patterns (29).  
Type-I and type-II IFs are comprised of the acidic and neutral-basic 
keratins, respectively, and are expressed mainly in epithelial cells (30). Four 
different proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and 
peripherin, are classified together as type-III IFs. Vimentin is the most widely 
expressed of all IFs and is found in endothelial cells, epithelial cells, and 
mesenchymal cells such as fibroblasts (31). The other members of the type-III 
IFs have a limited distribution, with desmin in muscle cells, GFAP in glial cells, 
and peripherin in the neurons of the PNS. Type-IV proteins include nestin, 
syncoilin, α-internexin, and the neurofilament triplet proteins that together 
comprise the neuronal IF network (32). The individual triplet proteins were initially 
described based on their molecular weight; therefore, they were called the 
neurofilament light (NF-L), neurofilament medium (NF-M), and neurofilament 
heavy (NF-H) proteins (29). Type-V IFs are composed of the lamin proteins, 
which form the nuclear lamina on the interior of the nuclear envelope (33). In 
contrast to the other four types of cytosolic IFs, the type-V lamins are restricted to 
the nucleus. 
 Despite vast differences in head and tail domain amino acid sequence, the 
conserved central rod domain allows all classes of IF to assemble in a similar 
stepwise process to form the filamentous network of the cell. For each type of IF, 
the α-helical rod domains of two proteins associate in a parallel and non-
staggered manner to form a coiled-coil dimer (34-37). Two dimers then pair 
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together in an antiparallel and half-staggered fashion to create a soluble tetramer 
that functions as the basic IF subunit (28). Next, eight tetrameric subunits 
associate laterally to form a unit length filament, which then progressively anneal 
end-to-end to eventually form the full length immature IF structure (38-42). Once 
the structure is in place, the filaments undergo an internal reorganization by 
radially compacting to form the mature 10 nm diameter filaments (43, 44). These 
discrete mature filaments then coalesce to create an extensive and complex IF 
network that spans the entire cytosolic space from the nucleus to cell membrane 
(45-47).  
Once this intricate array is formed, IFs generally function as the primary 
structural elements of the cell and are critical to maintaining the overall cellular 
shape (35, 48). Goldman and colleagues (49) demonstrated this function in 
fibroblasts by using a peptide mimetic that bound to the central α-helical rod 
domain of native vimentin IFs and inhibited the dimerization of vimentin 
monomers . Without the ability to construct full length filaments, the vimentin 
network in these fibroblasts was destabilized and eventually disassembled. 
Concurrent with this disassembly, the fibroblasts drastically changed their overall 
structure by retracting their filopodia and acquiring an exclusively rounded shape. 
Similar shape alterations have also been demonstrated in cells of the nervous 
system, as depleting the IF network through knockdowns of GFAP in glial cells 
and peripherin in PC12 cells inhibited each cell line’s ability to form peripheral 
processes and neurites, respectively (50, 51). Collectively, these experiments 
indicated a universal function of cell shape determination for all classes of IFs. 
6 
 
In addition to their function in maintaining overall cellular shape, IFs have 
also been shown to regulate the intracellular shape by controlling the distribution 
of multiple organelles such as the nucleus, Golgi apparatus, and mitochondria 
(52-54). This IF-mediated distribution is especially critical for mitochondria, as 
studies in mice have shown that mice lacking the expression of the muscle-
specific desmin IF have altered mitochondrial morphology and distribution. The 
mitochondria defect eventually leads to cardiovascular lesions and a dilated 
cardiomyopathy (54-56). These experiments demonstrate that all classes of IFs 
function as both mechanical integrators of intracellular space and primary 
determinates of cellular shape. 
 For many years, the role of maintaining overall cellular architecture was 
attributed to IFs being stable and static structures. These assumptions were 
based on the unique biochemical properties of IFs in relation to the other highly 
dynamic microfilaments and microtubules. During protein extraction, high 
concentrations of salts and detergents solubilize most cellular proteins, including 
actin and tubulin, but only small pools of soluble IFs were recovered (57). The 
remaining IF structure could be isolated as full length, insoluble filaments (58). 
These unique biochemical properties demonstrated that the polymerization of IFs 
creates an extremely stable structure and led to the assumption that there was 
little subunit exchange on the mature filament due to the lack of soluble IF 
intermediaries.  
 Despite the initial labeling as a static structure, more recent experiments 
revealed a more dynamic and mobile IF network than had previously been 
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hypothesized. The dynamic properties of IFs were demonstrated by monitoring 
the ectopic expression of IFs in transfected cells by immunofluorescence at 
different time points. These studies revealed that newly synthesized IFs are 
incorporated into the endogenous network at numerous discrete sites throughout 
the entire length of each filament in a process termed dynamic subunit exchange 
(59-61). Additional time-lapse observation using green fluorescent protein (GFP) 
fusion proteins further confirmed this process of dynamic subunit exchange, and 
also showed that individual filaments and smaller IF subunits are in perpetual 
motion without changing the overall cellular shape (62, 63).  
 The constant flux of IFs was also shown to involve the fast and 
discontinuous movement of IF subunits that could not be explained by simple 
diffusion alone (64). Instead, an intact microtubule network was required for this 
dynamic movement as microtubule disassembly disrupted the motion of IF 
subunits and forced the majority of IFs into juxtanuclear cap (65, 66). This 
dependence on microtubules and rate of motion suggested that the microtubule-
based motors kinesin and dynein were responsible for IF subunit motility. Indeed, 
moving IF subunits were shown to colocalize both motor proteins and disrupting 
this interaction had dramatic effects on the IF network (65, 67). By blocking the 
association between microtubules and kinesin, all kinesin-mediated plus-end 
transport was disrupted, and a subsequent collapse of the IF network into a 
compacted perinuclear aggregate was observed (65, 68). In contrast, enhanced 
kinesin binding resulted in increased plus-end transport and accumulation of IFs 
in the cellular periphery (67). Taken together, these findings demonstrate that IFs 
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compose a constantly fluctuating network that is mediated by microtubule based 
motors and is critical for the structural integrity of the cell. 
 
Generalized IF dysfunction in GAN 
  As the principal structural elements of the cell, IFs are indispensable for 
proper cellular function and abnormalities in the IF network have debilitating 
consequences.  Dysfunction of the IFs has been described as the primary 
determinant for many genetic diseases, such as epidermolysis bullosa simplex 
(EBS). EBS is a rare autosomal dominant disease characterized by bullous skin 
lesion that occur in response to minor injuries or abrasions (69). The disease is 
caused by mutations in the keratin intermediate filament protein, which is 
expressed in the keratinocyte cells that compose the epidermis (70). During 
keratin network assembly, the abnormal keratin expressed from the mutant allele 
binds to the normal keratin expressed from the normal allele and prevents any 
further IF polymerization (71). The lack of polymerization impedes the formation 
of the mature IF network and causes the basal keratinocytes to become fragile 
and easily damaged in response skin perturbations (69). This disease 
demonstrates the structural importance of IFs and shows that mutations in one 
type of IF can have devastating effects. 
 Abnormal IF structure serves as the genetic basis for a multitude of other 
diseases including NF-L mutations in Charcot–Marie–Tooth disease type-2 (72), 
NF-H mutations in amyotrophic lateral sclerosis (73), and lamin-A mutations in 
Hutchinson–Gilford progeria syndrome (HGPS) (74). HGPS is a rare genetic 
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disease characterized by the appearance of marked premature aging. The 
mutant lamin-A produced in patients is improperly processed and becomes 
permanently affixed to the inner nuclear membrane, thus preventing its 
incorporation into the normal nuclear lamina (33). Acting in a dominant gain-of-
function manner, the mutant lamin disrupts the normal lamin structure and 
eventually leads to severely disrupted nuclear structure and function (75). 
Collectively, these diseases are caused by mutations in one type of IF, which 
proceeds to compromise the mechanical integrity of any cell expressing that 
particular IF. 
 Unlike these other IF disorders, GAN is unique in that multiple classes of 
IFs are abnormal in numerous different cell types. In addition to the neurofilament 
accumulations in neurons, GAN patients also display aggregated IFs in other 
cells of the nervous system such as astrocytes, Schwann cells, endoneurial 
fibroblasts, and perineurial cells (10, 11, 76, 77). Abnormal IF structure has also 
been observed in cells outside the nervous system, for instance, muscle fibers, 
endomysial fibroblasts, endothelial cells, and pericytes (11, 19, 78, 79). In 
addition, altered keratin IFs are believed to cause the remarkably curly hair 
phenotype of GAN patients (16, 80). Since these affected cells express several 
different types of IFs, this suggests that GAN is not a disease of a single IF class, 
but rather that GAN is a disorder of generalized cytoplasmic IF disorganization. 
 This overall IF disorganization is also observed in dermal fibroblasts 
isolated by skin biopsy, which display a collapsed IF network that is retracted 
from the cell periphery and gathered into a discrete cytoplasmic mass near the 
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center of the cell, as determined by fluorescence microscopy (77, 81, 82). This 
mass is composed of the type-III IF protein, vimentin, and forms either an 
aggregate adjacent to the microtubule-organizing center, or a perinuclear ring 
that encircles the nucleus (83, 84). In normal growth conditions utilizing medium 
containing over 2% fetal bovine serum (FBS), vimentin aggregates are only 
observed in an average of 3% to 15% of GAN fibroblast cells (82, 84). Although 
this collapsed vimentin network is constitutively apparent in a subset of GAN 
fibroblasts grown in normal culture conditions, the phenotype is aggravated upon 
serum starvation. GAN cells grown in low serum conditions (0.1% FBS) exhibit a 
retraction of the vimentin network away from the cell periphery and vimentin 
aggregation is enhanced in an average of 48% to 88% of GAN cells, depending 
on the patient cell line (82, 84, 85). Similar induction of vimentin aggregates is 
also observed upon prolonged culture confluency and as a function of passage 
number, with a higher percentage of cells containing aggregates as the passage 
number increases (84, 86).  
Despite this dramatic induction of vimentin rearrangement, the actin and 
microtubule networks are unaltered in GAN cells and remain indistinguishable 
from control fibroblasts in any of the previously described conditions that affect IF 
structure (82-86). In all conditions, IF aggregates appear to form from a distinct 
subpopulation of vimentin filaments that normally populate the IF network. When 
assayed by immunoblotting or quantitative proteomics, there is no increase in 
vimentin synthesis and no significant difference in the amount of vimentin 
between GAN and control fibroblasts (86-89). These quantitative techniques 
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demonstrate that the formation of vimentin aggregates in GAN fibroblasts is not a 
result of increased IF protein levels, but rather result from a disorganization of the 
existing vimentin structure. This disorganized vimentin structure resembles the 
altered neurofilament network observed in GAN neurons and allows GAN 
fibroblasts to be used as a cell culture model to study the molecular mechanisms 
of the disease. Altogether, the generalized IF abnormalities in multiple GAN cell 
types suggests a defect in a more ubiquitously expressed protein that regulates 
IF structure, as opposed to a single defect in one class of IF. 
 
The GAN gene and encoded gigaxonin protein 
  Although GAN was classified as a genetic disease soon after its initial 
description in the 1970’s, the genetic defect causing these IF abnormalities 
remained elusive (1, 78). Homozygosity mapping of three patient families in 1997 
confirmed the autosomal recessive inheritance of GAN and localized the gene 
locus to chromosome 16q24.1 (90). Further refinement by Bomont and 
colleagues (91) lead to the identification of a single gene responsible for the 
disease, simply called the GAN gene, which was found to encode for a novel 68 
kilodalton (kDa) protein that was named gigaxonin (Giga) . Giga is a ubiquitous 
low abundance protein that is expressed evenly throughout the PNS and CNS; 
lower levels of expression are also seen in the heart, muscle, liver, and kidneys 
(85, 92, 93). After identification of the gene and encoded Giga protein, more than 
40 distinct mutations have been identified in the GAN gene of patients (94). 
These mutations are distributed evenly throughout the entire coding sequence 
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and include missense and nonsense mutations, insertions, and deletions (3, 9, 
25, 91, 95-97). Although the type and location of the mutation are variable 
between cases, all GAN patients have greatly decreased Giga protein levels 
ranging from 0.7% to 36.6% of unaffected controls (16, 85, 93). The deceased 
Giga protein levels are not the result of altered transcription since GAN patients 
have Giga mRNA levels commensurate or even higher than controls, but are 
rather caused by the mutant Giga in all GAN cases being highly unstable (16, 
95). This instability is the result of a shorter protein half-life for GAN-linked 
mutations, as mutant Giga exhibits a half-life ranging from 1 to 3 hours, whereas 
control Giga has a half-life of about 10 hours (16). Although GAN-linked 
mutations were shown to confer Giga protein instability, the function of Giga and 
its role in the pathogenesis of the disease remained elusive. 
 The first insights into Giga function came from bioinformatics analyses, 
which identified Giga sequence similarity to the ‘Broad complex, Tramtrack, Bric-
a-brac’ (BTB)-Kelch family of proteins. Like other members of the BTB-Kelch 
family, Giga contains an N-terminal BTB domain and a C-terminal domain 
composed of six kelch motifs (91). In a prototypical BTB-Kelch protein, the BTB 
domain mediates protein-protein interactions and regulates homomeric or 
heteromeric dimerization (98, 99). Similarly, the Kelch repeats assemble in a β-
propeller structure that also facilitate protein-protein interactions (100). With both 
N- and C-terminal domains mediating protein-protein interactions, members of 
the BTB-Kelch family have been shown to function as substrate adaptors that 
play a critical role in the ubiquitin-proteasome system (101). 
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Regulation of the ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) is a highly regulated cascade that 
allows temporal and specific degradation of proteins through targeted proteolysis. 
Targeting of proteolytic substrates occurs via the energy dependent conjugation 
of ubiquitin, a highly conserved 76 amino acid polypeptide, to the ɛ-amino group 
of a substrate lysine residue (102, 103). Multiple ubiquitin proteins can be added 
to the substrate to form a ubiquitin chain in a process called polyubiquitination. 
Polyubiquitinated proteins are then selectively targeted to the proteasome, which 
is a multisubunit energy dependent protease responsible for protein degradation 
(102, 104). This regulated protein degradation provides an irreversible process to 
promptly and specifically decrease target protein levels. 
 Regulation of the UPS is required to prevent nonspecific proteolysis and 
involves several steps to ensure targeted protein degradation (105). The first 
step in the cascade is ubiquitin activation by the E1 ubiquitin-activating enzyme, 
whose active-site cysteine forms a thiol ester with the C-terminal carboxylate of 
ubiquitin in an energy dependent reaction (106, 107). Activated ubiquitin is then 
receptive to nucleophilic attack by the E2 ubiquitin-conjugating enzyme that 
transiently transports the activated ubiquitin as a thiol ester using its active-site 
cysteine (102). The third step involves the E3 ubiquitin ligase specifically binding 
the proteolytic substrate and the subsequent formation of a complex between the 
substrate bound E3 and the E2 with the activated ubiquitin (104). Once the 
complex is formed, the E3 catalyzes the transfer of activated ubiquitins from the 
E2 to a substrate lysine residue, thus resulting in a polyubiquitinated substrate 
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(108). In the fourth step of the cascade, the polyubiquitinated substrate is 
delivered to the proteasome, which recognizes the polyubiquitin chain as a signal 
to degrade the substrate (108). Once it is received by the proteasome, the 
substrate is unfolded in an energy dependent manner, the proteasome removes 
the polyubiquitin chain, and the unfolded substrate enters the proteasome by 
facilitated diffusion (109). Degradation occurs when the substrate enters the 
central chamber of the proteasome, which contains the protease active sites that 
degrade the substrate into short polypeptides that are subsequently recycled for 
new protein synthesis (104). This cascade utilizing multiple enzymes allows for 
efficient degradation of a diverse population of substrates in a targeted and 
specific manner. 
 The enzymes of the UPS cascade are organized in a hierarchical fashion 
to allow for the increasing specificity needed to facilitate targeted ubiquitination. 
This hierarchy contains a single E1 that activates ubiquitin for all downstream 
conjugating enzymes (110). More diversity is observed for the E2 enzymes, with 
35 human versions identified so far (111). All E2 enzymes share a conserved 
core domain of about 150 amino acids, but variable N- and C-terminal regions 
allow each E2 to associate with several different E3 enzymes (111). Compared 
to the single E1, the increased number of E2 enzymes allows the activated 
ubiquitin to be distributed in an efficient manner to the most diverse portion of the 
hierarchy, which is composed of the E3 ubiquitin ligases. E3 enzymes are 
responsible for targeting the proteolytic substrate, therefore conferring substrate 
specificity to the UPS. This specificity is reflected in the number of E3s, as almost 
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a thousand have been characterized (112). Despite the vast array of E3s, all can 
be categorized into one of four classes based on their specific structural motif: 
HECT (homologous to E6-AP C-terminus)-type, PHD (plant homeodomain)-
finger-type, U-box-type, or RING (really interesting new gene)-finger-type  (112). 
The largest of these classes is the RING-finger-type E3s, which itself is divided 
into subclasses that include the cullin-RING ligases (CRLs).  
CRLs are multisubunit E3 complexes that are assembled onto a cullin 
protein that functions as a scaffold on which the rest of the E3 is assembled 
(113). Human cells express seven highly homologous cullin proteins that have 
similar structures containing an elongated protein with a central core domain that 
is flanked by distinct protein binding domains located on N- and C-terminal (101, 
114). The C-terminal of the cullin scaffold has a highly conserved domain that 
binds to the RING protein, which in turn functions as a binding site for an 
activated E2 ubiquitin-conjugating enzyme (114, 115). On the opposing end of 
the cullin, the N-terminal domain contains a variable sequence that interacts with 
specific adaptor proteins (114, 115). These adaptor proteins function to bind 
specific targeted substrates and chaperone them into the CRL complex where 
ubiquitin can then be transferred from the cullin-RING-bound E2 to the adaptor-
bound substrate (116). Therefore, the substrate adaptors provide the CRL with 
the substrate specificity needed for targeted and precise degradation. 
In addition to conferring specificity to the CRL, the utilization of substrate 
adaptors also allows for the central cullin-RING complex to associate with 
numerous different adaptors that can target diverse substrates to the common 
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core E3 (101). This targeting of adaptors and bound substrates to the core CRL 
is not universal, however, as not all classes of substrate adaptors can bind to 
each type of cullin. Instead, the cullin-substrate adaptor interaction is mediated 
by the variable cullin N-terminal domain and limits each cullin to only interacting 
with a specific class of substrate adaptors (117). Although their associations are 
restricted to one class of substrate adaptors, each cullin can interact with 
numerous substrate receptors of the same class (101). For example, the cullin-3 
(Cul3) protein specifically interacts with numerous substrate adaptors that 
contain an N-terminal BTB domain (99, 118-122). These various BTB proteins 
also have a C-terminus comprised of either a zinc finger, meprin and TRAF 
homology (MATH), or Kelch domain that facilitates substrate binding (117). 
Therefore, these BTB proteins contain an N-terminal domain that permits binding 
to Cul3 and a C-terminal domain that recruits substrates for ubiquitination. 
Collectively, this domain structure allows for these BTB proteins to function as 
efficient substrate adaptors (98). Indeed, numerous BTB proteins have been 
validated as substrate adaptors for CRL, with one class being the BTB-Kelch 
proteins that includes Giga (100, 123). The sequence similarity of Giga to other 
BTB-Kelch proteins supports the hypothesis that Giga functions as substrate 
adaptor in a multisubunit CRL to facilitate the UPS-mediated degradation of 
currently unknown substrates (Figure 1). 
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 Figure 1: Giga functions as a substrate adaptor for an E3 ubiquitin ligase. 
Giga binds substrates through its C-terminal Kelch repeat domains and 
subsequently assembles into the E3 complex via its N-terminal BTB domain. 
Once the E3 complex is formed, multiple ubiquitins are transferred from the E2 
ubiquitin-conjugating enzyme to the substrate. The polyubiquitinated substrate is 
then delivered to the proteasome and degraded. Figure modified from Petroski 
and Deshaies, “Function and regulation of cullin–RING ubiquitin ligases” (101). 
 
Gigaxonin functions as a substrate adaptor 
 Although Giga contains the protein binding domains of a canonical 
substrate adaptor, verification of this function requires experimental evidence for 
Giga binding to both Cul3 and targeted substrates via its BTB and Kelch 
domains, respectively. Confirmation of these associations, however, has proven 
to be difficult due to the transient nature of the CRL complex formation and the 
low expression levels of native Giga (85, 121). Despite these difficulties, the BTB 
domain of Giga has been shown to bind Cul3 and facilitate Giga’s assembly into 
a CRL, thus supporting its role as a substrate adaptor (120, 123). Further 
validation of Giga’s substrate adaptor function came when three different proteins 
were reported as substrates of Giga (93, 124-126). This ability to bind multiple 
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substrates is not unique to Giga, as many other substrate adaptors demonstrate 
the ability to facilitate the ubiquitination and degradation of multiple proteins 
within a similar pathway (127-133). 
 The first Giga-mediated substrate interaction was identified when Giga 
was shown to bind microtubule-associated protein 1B (MAP1B) (93). The MAP1B 
protein functions in microtubule dynamics by binding tubulin subunits, promoting 
their polymerization into microtubules (134). By increasing tubulin polymerization, 
MAP1B has a stabilizing effect on the microtubule structure and is critical in 
complex cells such as neurons (135, 136). Accordingly, MAP1B deficient 
neurons display inhibited axon formation due to a delay in axon outgrowth; this 
axonal phenotype made MAP1B an intriguing possible substrate of Giga in the 
context of GAN (137, 138). Interactions between Giga and MAP1B were first 
identified using a yeast two-hybrid system and were subsequently verified by co-
immunoprecipitations (93). Additionally, the binding of MAP1B was shown to 
occur via the Kelch substrate binding domain of Giga, thus further confirming 
MAP1B as a Giga substrate (93). As substrate adaptors control the degradation 
of their targets, the protein levels of the two are inversely related; that is, as 
protein levels of the adaptor decrease, a consequential increase in substrate is 
observed due to its impaired degradation. This relationship was demonstrated for 
Giga and MAP1B, as the absence of Giga in GAN knock-out mice led to 
significantly increased MAP1B protein levels (124). The inverse was also shown 
by Giga overexpression, which resulted in a protein clearance of MAP1B that 
was dependent on the proteasome (124). Together, these experiments support 
19 
 
the model that Giga functions as a substrate adaptor that targets MAP1B for 
proteasome mediated degradation. 
 A second substrate of Giga is tubulin-folding cofactor B (TBCB), which is 
one of several tubulin-folding cofactors that controls microtubule dynamics by 
promoting the depolymerization of microtubules (139, 140). Specifically, TBCB 
dissociates the α and β tubulin heterodimer and subsequently sequesters the 
free α-tubulin subunit to prevent reformation of the functional tubulin dimer (141, 
142). The association of TBCB and Giga was initially identified with a yeast two-
hybrid screen and verified by co-immunoprecipitation, which further showed the 
Giga Kelch domain was responsible for the interaction (125). As predicted for 
adaptor and substrates, these proteins were found to be inversely related, as 
elevated protein levels of TBCB were observed in gigaxonin-null mice (125). 
Additionally, Giga overexpression in cell culture resulted in significantly 
decreased TBCB protein levels that were dependent on proper proteasome 
function (125). These results also demonstrate all the necessary elements of an 
adaptor-substrate interaction and indicate that TBCB is a substrate of Giga. 
 A third Giga substrate is microtubule-associated protein 8 (MAP8) (126). 
Akin to the previously described member of microtubule-associated protein, 
MAP8 binds tubulin subunits and stabilizes the overall microtubule structure 
(143, 144). Giga binds to MAP8 and controls its proteasome mediated 
degradation in a similar fashion as the other identified substrates (126). Taken 
together, the three identified Giga substrates of MAP1B, TBCB, and MAP8 are all 
classified as microtubule-associated proteins (MAPs) due to their ability to bind 
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microtubules and alter microtubule dynamics, thus suggesting a role for Giga in 
controlling the microtubule structure through the degradation of these three 
MAPs. 
The implied role for Giga in microtubule dynamics, however, does not 
appear to conform to experimental observations, as the microtubule structure is 
unaltered in GAN cells (82, 83). The only reported GAN cytoskeletal defect is 
disorganized IF structures, and no changes in tubulin protein levels or 
microtubule organization have ever been reported (84-86, 145). This lack of a 
connection between Giga and the microtubule structure led to further scrutiny of 
the purported Giga substrates and the emergence of conflicting reported 
experiments. The original experiments identifying MAP1B, TBCB, and MAP8 as 
Giga targets all used either GAN knockout mice or overexpression systems to 
confirm Giga-substrate binding, show substrate accumulation in the absence of 
Giga, and demonstrate proteasome mediated degradation of the substrates (93, 
124-126). Multiple other studies have since attempted to reproduce these results 
in primary GAN patient cells, but none have been successful. In contrast to the 
original studies, the protein levels of TBCB and MAP1B were found to be 
unaltered in GAN cells, thus minimizing the likelihood that they are Giga 
substrates (85, 86, 145). These conflicting results may be the result of non-native 
associations that occur with Giga overexpression or defects in the GAN knockout 
mouse model used to identify the substrates. To date, three GAN mouse models 
have been created but each exhibit only moderate behavioral, motor, and 
sensory deficits that do not recapitulate the severity of the human disease (92, 
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126, 146). Additionally, independent analysis of these knockout mice failed to 
demonstrate the significant increases of MAP1B, TBCB, and MAP8 that were 
originally described (92). This discrepancy in reported protein levels, coupled 
with the lack of microtubule phenotype in GAN, has brought into question the 
validity of MAP1B, TBCB, and MAP8 as Giga substrates. 
To obtain a better understanding of Giga substrates, Mussche and 
colleagues (89) utilized differential proteomics in conjunction with mass 
spectrometry to compare protein levels between control and GAN fibroblasts . 
This strategy was reliant on the substrate adaptor function of Giga, as the loss of 
Giga in GAN cells would result in impaired substrate degradation and ultimately 
lead to their accumulation which could be quantified in the assay. The results 
from these experiments identified 72 known structural cytoskeletal proteins, but 
no significant differences in protein abundance were observed between control 
and GAN cells. Among the quantified cytoskeletal proteins, both vimentin and 
MAP1B were not found to be accumulated in GAN cells. The assays failed to 
identify either TBCB or MAP8, however, most likely due to their low expression in 
fibroblasts. Although the proteomic approach failed to implicate any proteins 
previously associated with GAN, five other proteins were found to have a 
significantly higher abundance in GAN cells and are potential substrates of Giga. 
The most significantly upregulated protein was galectin-1, and analysis of its 
function demonstrated an intriguing possibility for galectin-1 involvement in the IF 
abnormalities of GAN. 
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Galectin-1 and Ras stabilization  
  The galectins are a conserved family of β-galactoside binding proteins 
that share a consensus carbohydrate recognition domain responsible for their 
inherent ability to bind polysaccharides (147). Galectins are ubiquitously 
expressed, as almost all cells express at least one of the fifteen mammalian 
galectins that have been identified (148, 149). Although the galectin family of 
proteins is highly conserved, each member differs in their affinity for different 
polysaccharide chains (150, 151). This lectin function leads to galectin interaction 
with a wide variety of glycoproteins, and allows galectins to modulate a diverse 
group of biological pathways such as homeostasis, apoptosis, and 
embryogenesis (152-156). 
 The galectin family member of interest in the context of Giga-targeted 
protein ubiquitination is galectin-1 (Gal-1), as Gal-1 protein levels were found to 
be significantly elevated in GAN cells (89). Like other galectins, Gal-1 is widely 
expressed and high protein levels of Gal-1 were noted in the PNS and CNS (149, 
157-159). The function of Gal-1 is dependent upon its localization, as Gal-1 
exhibits dual localization in the intracellular and extracellular space (160, 161). In 
the extracellular space, Gal-1 function is dependent on its lectin activity and Gal-
1 has been shown to bind to various polysaccharides and glycoproteins (162, 
163). For example, extracellular Gal-1 has been show to bind specifically to N-
glycosylated β-integrins and transiently promote activation of the integrin 
complex (164). In contrast to the lectin based extracellular activity, the 
intracellular function of Gal-1 has been demonstrated to be independent of 
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polysaccharide binding and has been attributed to specific protein-protein 
interactions (149). The most prolific of these intracellular protein based 
interactions involve the lactose-independent binding of Gal-1 to the Ras proteins 
(165). 
 Ras proteins function as molecular switches in the plasma membrane that 
transduce extracellular signals into different intracellular signaling cascades. This 
activity of the Ras switch is controlled by guanosine triphosphate (GTP) binding, 
as Ras proteins alternate from an active GTP-bound state to an inactive 
guanosine diphosphate (GDP)-bound state (166). The formation of activated Ras 
is catalyzed by guanine nucleotide exchange factors (GEFs), which are recruited 
to the plasma membrane in response to activated receptor tyrosine kinases. This 
membrane localization facilitates their interaction with Ras and allows the GEFs 
to activate Ras by catalyzing the exchange of GDP to GTP (167, 168). The 
binding of GTP induces conformational changes in Ras that permit Ras 
interaction with a variety of downstream effects for the duration of the Ras-GTP 
interaction (169, 170). To inactivate Ras signaling, hydrolysis of GTP is 
necessary. Although Ras has an intrinsic GTPase activity, its activity is too low to 
allow efficient termination of the signaling cascade (168, 171). Therefore, Ras 
inactivation requires the activity of GTPase-activating proteins (GAPs), which 
enhance the intrinsic Ras GTPase activity and allow Ras to cycle back to its 
inactive GDP-bound form (168). The utilization of GEFs and GAPs allows Ras to 
function as a binary switch that controls the rapid and transient transduction of 
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signals to intracellular effectors. These effectors are involved in multiple cellular 
process, including homeostasis, differentiation, and survival. 
 The Ras protein family is composed of three ubiquitously expressed 
isoforms: H-Ras, K-Ras, and N-Ras. The Ras isoforms are highly homologous, 
with each sharing 85% amino acid sequence identity. This similarity allows all the 
Ras isoforms to transmit their signals through similar effector proteins, such as 
Raf, phosphoinositide 3-kinase (PI3K), and Ral-GDS (166, 170). Despite many 
mechanistic similarities, the Ras isoforms possess distinct cellular functions. This 
idea was best demonstrated using individual Ras isoform knockout mouse 
models, which showed that only K-Ras was essential for normal mouse 
development, whereas both H-Ras and N-Ras were dispensable (172-175). 
These biological differences are attributed to a 25 amino acid variable domain in 
the C-terminus of each isoform, termed the hypervariable region (HVR), for which 
the Ras isoforms share as 15% sequence identity (176). This region is essential 
for interaction with downstream effector proteins, and the differences in the HVR 
are believed to cause isoform-specific effector interactions that activate distinct 
intracellular signaling cascades with varying affinities (177-182). 
 In addition to its role in effector binding, the HVR has also been shown to 
be critical for the proper membrane localization of all Ras proteins. The HVR 
contains a common tetrapeptide CAAX (C-cysteine, A-aliphatic amino acid, and 
X-any amino acid) sequence that is essential for a series of post-translational 
modifications required for Ras membrane localization (183). In the first step of 
this sequence, a farnesyl group is attached to the cysteine residue of the CAAX 
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tetrapeptide by the farnesyltransferase enzyme (184). This farnesylation then 
targets the Ras protein to the endoplasmic reticulum, where the Rce1 
endopeptidase removes the AAX tripeptide, and the newly generated C-terminal 
farnesylcysteine is subsequently methylated by isoprenylcysteine carboxyl 
methyltransferase (185-189). Following methylation, the Ras isoforms take one 
of two pathways to become fully integrated into the plasma membrane, which is 
reliant upon a second C-terminal targeting signal. The first pathway involves the 
palmitoylation of upstream cysteine residues in the HVR of H-Ras and N-Ras 
(190). This transfer of a palmitoyl moiety allows H-Ras and N-Ras to be trafficked 
through the exocytic pathway via the Golgi and permits subsequent anchoring in 
the plasma membrane (185, 191). The second pathway involves K-Ras, which 
lacks the HVR cysteine residues required for palmitoylation, but instead contains 
a positively charged polylysine sequence that permits the Golgi-independent 
trafficking of K-Ras to the membrane in an unknown mechanism (190, 192). This 
finding demonstrates that the HVR of the Ras isoforms provides subtle 
differences in sequence that can lead to substantial differences in effector 
binding and traffic to the membrane. 
 The HVR not only alters Ras trafficking to the membrane, but also alters 
the localization of each Ras isoform in the plasma membrane, which is a 
complex system of microdomains. Microdomains are highly ordered areas of the 
membrane that contain distinct lipid and protein compositions which allow the 
isolation of different signaling molecules to increase signaling efficiency (193). 
Ras microdomain localization has proven to be dependent on its post-
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translational modifications, as the palmitoylated H-Ras and N-Ras are found in 
lipid rafts while the non- palmitoylated K-Ras is localized to the disorganized bulk 
membrane outside of the lipid microdomains (194, 195). Once attached to the 
membrane, the Ras proteins are highly dynamic and continuously moving 
between different membrane microdomains by lateral diffusion (196). This 
dynamic motion has especially been demonstrated for H-Ras, as its microdomain 
localization is dependent on its activation state. The majority of inactive H-Ras-
GDP is found in lipid microdomains, but the exchange of GDP for GTP 
redistributed the activated H-Ras from the lipid raft to the disorganized bulk 
membrane, which therefore is the primary site of H-Ras signaling (194, 195, 197, 
198). This dynamic motion of H-Ras is dependent on the HVR, and particular 
protein interactions with this domain have been shown to influence H-Ras 
localization and function. 
 One such H-Ras interacting protein is Gal-1, which was previously shown 
to be significantly elevated in GAN cells. Gal-1 specifically binds the membrane 
bound H-Ras isoform, while K-Ras and N-Ras show minimal association with 
Gal-1 (165). Additionally, the specific interaction between Gal-1 and H-Ras is 
dependent upon activation state, as the GTP bound H-Ras binds Gal-1 more 
efficiently than the inactive form (199). Once bound, Gal-1 stabilizes activated H-
Ras by attenuating the GAP-facilitated GTP hydrolysis and driving the formation 
of transient nanoclusters in nonraft microdomains (200-202) (Figure 2). These H-
Ras nanoclusters contain six to eight closely associated activated H-Ras proteins 
that serve as a signaling platform to efficiently transmit signals to downstream  
27 
 
 Figure 2: Gal-1 stabilizes GTP bound H-Ras and forms activated Ras 
nanoclusters. (A) Inactive H-Ras-GDP is found primarily in lipid rafts, which are 
enriched with sphingolipids and have high concentrations of cholesterol. The 
GEF-catalyzed activation of H-Ras redistributes the H-Ras-GTP into the bulk 
membrane, which is composed of mostly phospholipids. (B) Gal-1 stabilizes 
activated H-Ras in the bulk membrane and drives the formation of transient H-
Ras nanoclusters. These nanoclusters serve as platforms to efficiently transmit 
the activated H-Ras signal to downstream effector proteins.  
 
effector proteins (203). Therefore, increased Gal-1 levels lead to a stabilization of 
H-Ras nanoclusters that ultimately result in increased effector activation. 
 In addition to increasing the effector output, Gal-1 also alters H-Ras 
association with its two main effector proteins, Raf-1 and PI3K. Specifically, 
activated H-Ras that is stabilized by Gal-1 has been shown to promote Raf-1 
activity while inhibiting signaling through PI3K (165, 199). This selectivity is due 
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to a conformational change in H-Ras which occurs during Gal-1 binding and 
permits binding to Raf-1 but disrupts binding to PI3K (199). Together this 
suggests a dual role for Gal-1 in Ras signaling, as Gal-1 not only specifically 
stabilizes the H-Ras isoform, but also provides effector selectivity by diverting 
downstream signaling to Raf-1 at the expense of PI3K. Once activated by Gal-1 
and H-Ras interactions, increased Raf-1 pathway signaling can potentially have a 
multitude of effects on the cell. One potential outcome of interest in the context of 
GAN is the phosphorylation of IFs, as Raf-1 associated kinases have been 
demonstrated to phosphorylate IFs at multiple sites (204). 
 
Role of intermediate filament phosphorylation  
 IF phosphorylation generally promotes the reorganization of the filament 
structure and modulates their dynamic movement in order to accommodate 
various physiological events. Phosphorylation mainly occurs on serine and 
threonine residues in the variable head and tail domains of the IF (205, 206). In 
most cell types, this modification inhibits IF subunit polymerization and promotes 
the disassembly of the preexisting IF structure (204, 207-209). Although this 
outcome has been demonstrated for various IFs in numerous cell types, the 
process of IF phosphorylation is best understood in the context of vimentin 
phosphorylation in fibroblasts (210-213). Vimentin contains 40 identified 
phosphorylation sites, which are modified by numerous protein kinases (206, 
209, 214, 215) (Figure 3). The effect of vimentin phosphorylation was first 
demonstrated by Lamb and colleagues in 1989 when they microinjected a known  
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Figure 3: Map of identified vimentin phosphorylation sites. (A) Distribution of 
vimentin phosphorylation sites on the N-terminal head domain, the central rod 
domain, and the C-terminal tail domain. (B) Magnification of the vimentin N-
terminal head domain noting the specific phosphorylation sites. All identified 
kinases responsible for each phosphorylation event are listed and noted by an 
arrow.  
 
vimentin kinase, protein kinase A (PKA), into fibroblasts and observed a prolific 
rearrangement of the vimentin structure (216). Succeeding the PKA injections, 
the filaments retracted from the periphery of the cell in a time dependent manner 
and eventually collapsed around the nucleus to form a tight perinuclear bundle.  
This phenotype occurred concurrently with a significant increase in PKA-
mediated vimentin phosphorylation, and led to the conclusion that vimentin 
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phosphorylation stimulates dynamic rearrangement of the IF structure. Similar 
results were also obtained by overexpressing other protein kinases, thus 
demonstrating the phenotype of phosphorylation-induced vimentin redistribution 
was not specific to one kinase or phosphorylation site but instead represented a 
more inclusive function of IF phosphorylation (204, 217, 218).  
 The vimentin network has also been shown to be modified via 
phosphorylation during normal cellular processes, such as mitosis (219). As cells 
enter mitosis, vimentin phosphorylation increases and the IF network is 
depolymerized to form non-filamentous cytoplasmic aggregates (208, 220-223). 
This drastic reorganization is required to disassemble the vimentin structure and 
thus allow partitioning of the constituted IF proteins into the daughter cells (224). 
To permit mitotic disassembly and subsequent reassembly in daughter cells, the 
phosphorylation of IFs is spatiotemporally regulated by distinct kinases (225, 
226). As the cell enters prophase, IF phosphorylation increases and the widely 
distributed IF network of interphase is retracted from the cellular periphery to 
form a centrosomal IF aggregate (206, 224). Subsequent phosphorylation on 
separate residues dissolves this aggregate into IF subunits that form a finely 
speckled pattern throughout the cytoplasm during metaphase (224, 227, 228). 
Next, the progression into anaphase and telophase coincides with a general 
decrease in vimentin phosphorylation and the reformation of short filaments, 
which are then reassembled into longer filaments that are concentrated in a 
juxtanuclear cap (206, 224, 229). Finally, phosphorylation at cleavage furrow-
specific sites during cytokinesis promotes the segregation of the IFs into 
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separate daughter cells (214, 224, 230). This dynamic disassembly and 
reorganization of IFs demonstrates the spatiotemporal control of IF structure by 
phosphorylation during vital cellular processes such as mitosis. 
 In addition to controlling the reversible polymerization of the IF structure in 
dividing cells, IF phosphorylation also contributes to cytoskeletal function in post-
mitotic cells such as neurons. The neuronal intermediate filament network is 
composed of neurofilaments (NFs) that form a stable structure after 
synaptogenesis that is not disassembled and reassembled like the IF network of 
a mitotic cell (231, 232). Although the NF structure is never completely 
reorganized, individual NFs are still dynamic and undergo extensive subunit 
exchange that allows the structure to be maintained (233, 234). This movement 
of NFs displays some similarities to the IF reorganization observed in mitotic 
cells, as phosphorylation also controls the dynamics of NFs through two related 
mechanisms. 
 The first mechanism altered by NF phosphorylation is the transportation of 
NFs, which move along the axonal microtubule structure by associating with the 
kinesin and dynein molecular motors (235, 236). Although NFs are transported 
using the conventional molecular motors, their movement proceeds at a 
significantly slower rate than any other cargo due to interrupted associations of 
the NF and motor (237). This dissociation results in periods of long pauses when 
the NF is unattached to the motor, followed by short intermittent bursts of rapid 
movement when they are attached that ultimately generates an overall slow rate 
of transport (238, 239). The rate of transportation is further modulated by NF 
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phosphorylation, which progressively restricts association with kinesin and 
promotes elongated transportation pauses (235, 240, 241). By promoting 
dissociation from kinesin, NF phosphorylation generates an anterograde rate of 
transport that is inversely correlated with its phosphorylation state (242, 243). In 
addition to inhibiting anterograde transport, NF phosphorylation also promotes 
retrograde transport by promoting NF association with dynein (236). Therefore, 
NF phosphorylation leads to accumulation of NFs in the proximal region of the 
axon by restricting anterograde transport and promoting retrograde transport. 
 The second mechanism by which phosphorylation alters NF dynamics is 
by increasing protein-protein interactions between the C-terminal domains of NFs 
(244). These domains contain multiple serine residues that extend from the 
filament to form side arms when phosphorylated (205, 243). The lateral 
projections conferred by the side arms normally control the spacing between 
adjacent full length filaments, but hyperphosphorylation of NFs disturbs these 
interactions and promotes attraction between the side arm and the core of 
adjacent polymers NF (245, 246). The NF attractions result in the formation of a 
bundle, which is a large NF accumulation that specifically contains 
phosphorylated NFs and selectively excludes non-phosphorylated forms (244, 
247, 248). Concurrent with the formation of these bundles, NF phosphorylation 
increases the axon caliber, as enlarged axons are observed in distinct regions 
containing increased NF phosphorylation and accumulation (232, 249).  
Collectively, NF phosphorylation promotes bundling and inhibits 
anterograde transport, thus leading to increased axon caliber due NF 
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accumulation in the proximal region of the neuronal axon. This phenotype is 
remarkably similar to that observed in GAN patient neurons and potentially could 
explain the ‘giant’ axons filled with disorganized neurofilaments. The 
phosphorylation of NFs in the context of GAN, however, has not been widely 
investigated. One report observed an increased phosphorylation in enlarged 
axons but the state of IF phosphorylation has not been documented in any other 
GAN cells type (19). This is of particular interest since a mechanism causing 
systemic IF hyperphosphorylation could explain the generalized IF 
disorganization that is observed for numerous in vivo GAN patient cell types. 
 
Summary and hypothesis 
 GAN is characterized by generalized IF abnormalities that result from Giga 
mutations. Giga normally functions as an E3 substrate adaptor in the UPS, and 
the loss of Giga function leads to accumulation of its substrates. One potential 
Giga substrate is Gal-1, which stabilizes activated Ras and promotes signaling 
through Raf-1 at the expense of PI3K. Raf-1 associated kinases phosphorylate 
IFs at multiple distinct sites and generally promote the disassembly or 
aggregation of IFs (Figure 4). This phosphorylated IF phenotype is reminiscent of 
the IF abnormalities observed in GAN patient fibroblasts and neurons. Taken 
together, this led us to hypothesize that Giga regulates IF phosphorylation and 
structure by modulating the Ras pathway through the degradation of Gal-1 
(Figure 5). 
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 Figure 4: Schematic of the proposed Giga-mediated signaling pathway. 
Giga controls the protein degradation of Gal-1, which normally stabilizes the 
activated form of H-Ras. The Giga-mediated degradation of Gal-1 allows for the 
maintenance of activated H-Ras levels in the cell and regulates the signaling to 
downstream effectors that can phosphorylate intermediate filaments.  
 
The objectives of this study were therefore fourfold: 1) Ascertain the IF 
phenotype of GAN patient cells and its relationship to an alteration in IF 
phosphorylation state, 2) Determine if replacing Giga can correct IF phenotype 
and phosphorylation, 3) Confirm Gal-1 as a substrate of Giga, and 4) Determine 
if the Gal-1 mediated Ras signaling pathway generates the IF abnormalities in 
GAN. 
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 Figure 5: Illustration of the proposed signaling pathway in GAN. (A) In 
control cells, Giga is expressed and can degrade Gal-1. Low levels of Gal-1 
permits the hydrolysis of Ras-GTP to inactive Ras-GDP. This leads to low levels 
of vimentin phosphorylation, which maintains normal vimentin polymerization and 
distribution. (B) In GAN cells, Giga is not expressed and Gal-1 accumulates. 
Increased levels of Gal-1 stabilize Ras-GTP and increase downstream vimentin 
phosphorylation. This increased phosphorylation promotes the disassembly of 
vimentin filaments and results in the formation of phosphorylated vimentin 
subunits that accumulate in the perinuclear region of the cell. 
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CHAPTER II: MATERIALS AND METHODS 
 
Cell culture 
Fibroblasts used included the de-identified GAN patient cell lines of 10-
W145 (GAN cell line 1) and F3245 (GAN cell line 2) (both gifts of Dr. Steven 
Gray, University of North Carolina at Chapel Hill School of Medicine). GAN cell 
line 1 was used as the representative GAN cells in all experiments unless 
otherwise noted. The unrelated fibroblast cell line GM01661 (Coriell 
Biorepository) was used as experimental controls. All cells were propagated in 
media composed of Dulbecco's modified Eagle's medium (DMEM; Life 
Technologies), supplemented with 10% fetal bovine serum (FBS; Thermo 
Scientific), 25.0 mM glucose, penicillin-streptomycin, sodium pyruvate, non-
essential amino acids, and GlutaMAX (all from Life Technologies). This complete 
growth media containing 10% FBS will henceforth be referred to as normal 
serum media. Alternatively, cells were cultured in a nonpermissive growth media 
composed of DMEM containing 0.1% FBS and the same supplements listed 
above. This nonpermissive growth media with 0.1% FBS will hereafter be termed 
low serum media. 
Cells were maintained at 37°C in a humidified, 5% CO2 incubator and 
were used for experiments at an intermediate passage number between passage 
twelve and seventeen. For all experiments, GAN or control cells were seeded 
into 35 mm dishes containing normal serum media. Sixteen hours later, the cells 
were washed with PBS and then incubated in either normal or low serum media 
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for 72 hours. After this three day incubation, the cells were then utilized for the 
specified experiment.  
 
Immunofluorescence and image acquisition 
GAN or control cells were seeded on 35 mm glass bottom coverslip dishes 
and then grown in low serum media for 72 hours.  The cells were subsequently 
rinsed with PBS and fixed in 4% paraformaldehyde (PFA) for 10 minutes at room 
temperature. To stop the fixation process, the cells were washed 3 times for 5 
minutes each in PBS containing 100 mM glycine. After fixation, cells were 
permeabilized and blocked in blocking buffer (4% bovine serum albumin and 
0.2% saponin in PBS) for 10 minutes at room temperature. The fixed cells were 
incubated with primary antibody diluted in blocking buffer for 1 hour at room 
temperature, washed 3 times in blocking buffer for 5 minutes each, and then 
processed with secondary antibody as was done for the primary. After washing, 
the cells were rinsed with PBS twice and then stored in PBS for imaging. The 
antibodies used were mouse anti-vimentin (EMD Millipore), goat anti-mouse 
Alexa Fluor 568 conjugate, mouse anti-alpha-tubulin Alexa Fluor 488 conjugate, 
and rabbit anti-GFP Alexa Fluor 647 conjugate (all from Life Technologies). 
The immunostained cells were imaged using the confocal Olympus 
Fluoview FV-1000 MPE system (Olympus America, Central Valley, PA) available 
at the Indiana Center for Biological Microscopy facility (Indianapolis, IN).  Images 
were obtained in a sequential illumination mode using 488nm, 568nm, and 
633nm lasers with Olympus water immersion objective lenses of either 20x 
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(UApoN340 20xW, NA 0.7) or 60x (UPlanSAPO 60xW, NA 1.2). Each image was 
acquired as a Z stack with 0.85µm between each frame. Images were comprised 
of 512x512 pixels (634 x 634 μm2) and compiled using Olympus FluoView 
Viewer (Version 2.0) imaging software. 
 
GAN phenotypic scoring 
 To measure the abnormal vimentin phenotype of GAN patient fibroblasts, I 
developed a new phenotypic scoring method using immunofluorescence that 
quantifies the restricted distribution of vimentin in patient cells. This 
measurement is based upon the unaltered tubulin structure in GAN patient 
fibroblasts, which is indistinguishable from controls, being used as a marker for 
the total cellular area. Once the total area was obtained, this was then be divided 
by the vimentin area to generate a ratio of vimentin area to total cellular area, 
which represents the cellular area that vimentin occupies. This area was then 
subtracted from one to obtain the cellular area without vimentin, or the vimentin 
free area (VFA) 
 To generate the area measurements, the image files were analyzed using 
ImageJ (NIH). The Z projection of the sum slices was used and any background 
was removed with the ROF denoise function. Automatic thresholding was then 
applied with the ‘Percentile’ algorithm to generate a binary image containing only 
positive or negative signal for each channel of tubulin or vimentin (Figure 6). The 
areas generated from these binary images, which represent the area of either 
tubulin or vimentin in each field of view, were then measured. The total area of  
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 Figure 6: Generation of threshold images to obtain tubulin and vimentin 
areas for quantification of the VFA. (A) Control cells with a tubulin (green) and 
vimentin (red) overlay. (B) Thresholded image of the tubulin signal in control 
cells. (C) Thresholded image of the vimentin signal in control cells. (D) GAN cells 
with a tubulin (green) and vimentin (red) overlay. (E) Thresholded image of the 
tubulin signal in GAN cells. (F) Thresholded image of the vimentin signal in GAN 
cells. 
 
tubulin was then divided by the total area of vimentin, and this ratio was 
subsequently subtracted from one to generate the VFA. 
Each experiment was comprised of four separate replicates for each 
condition. Every replicate consisted of at least seven images of different fields 
that were used to generate an average VFA for each experiment. Four separate 
replicates were then averaged to generate the VFA for each condition. 
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Western blot analysis  
GAN or control cells were seeded into 35 mm dishes and subsequently 
grown in normal serum media or low serum media for 72 hours.  The cells were 
then washed twice with ice cold PBS and then scraped into ice cold RIPA Buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% 
sodium deoxycholate), containing Halt protease and phosphatase cocktail 
inhibitor (Thermo Scientific). Protein concentrations were determined using the 
BCA protein assay kit (Thermo Scientific), and equal protein amounts were 
combined with Laemmli sample buffer. The whole cell lysates were separated on 
12% SDS-PAGE gels and subsequently transferred to polyvinyl difluoride (PVDF) 
membranes (EMD Millipore). The membranes were then blocked at room 
temperature for one hour in PBS-0.05% Tween-20 (PBST) supplemented with 
5% blotting-grade nonfat dry milk (Bio-Rad). After blocking, the primary antibody 
was diluted in 5% milk and incubated with the membranes at 4°C overnight. The 
membranes were washed with PBST four times for five minutes per wash, and 
then the corresponding horseradish peroxidase–conjugated secondary antibody 
was incubated with the membranes for 1 hour at room temperature. After 
washing with PBST four times for five minutes per wash, the blots were 
developed using SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific). Western blot signal intensities were determined by densitometry using 
ImageJ (NIH) software. The reported western blot quantifications were obtained 
from three independent experiments using the same cell line. 
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The primary antibodies used were anti-gigaxonin, anti-galectin-1, anti-
tubulin, and anti-GAPDH (Sigma-Aldrich), anti-vimentin and anti-phospho-
vimentin Ser83 (Cell Signaling Technology), anti-H-Ras, anti-K-Ras, and anti-N-
Ras (Santa Cruz Biotechnology), anti-MEK1 and anti-MEK2 (Bethyl 
Laboratories), anti-phospho-vimentin Ser39, anti-phospho-vimentin Ser51, and 
anti-phospho-vimentin Ser72 (MBL International Corporation), and anti-ubiquitin 
(Abcam). Secondary antibodies included horseradish peroxidase-conjugated 
goat anti-rabbit and goat anti-mouse (Bio-Rad), and goat anti-rat (Santa Cruz 
Biotechnology). 
 
Lentiviral production and transduction 
The lentiviral vector pCSCIGW (gift of Dr. Ken Cornetta and Dr. Daniela 
Bischof, Vector Production Facility, Indiana University School of Medicine), which 
contains an  internal ribosome entry site (IRES), was used for lentivirus 
production. To allow simultaneous expression of two proteins from the same 
transcript, a FLAG-tagged WT gigaxonin cDNA sequence was inserted into the 
upstream reading frame of the IRES and an eGFP sequence was inserted 
downstream of the IRES. Lentiviruses were produced by cotransfecting the 
resulting pCSCIGW-gigaxonin-IRES-eGFP transfer plasmid, the packaging 
plasmids of pMDL and pRSV-Rev, and the envelope plasmid of pMDG1, into 
293T cells (Life Technologies) using a calcium phosphate transfection system 
(Life Technologies). After 3 days, the culture supernatant was collected and 
filtered. The target GAN cells were then incubated with the viral supernatant 
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supplemented with 8 µg/mL polybrene (Santa Cruz Biotechnology), and after 8 
hours, the virus containing media was replaced with growth media. The 
transduced cells were grown for a total of 3 days and then sorted by 
fluorescence-activated cell sorting according to GFP expression. Additional 
sorting was done again 3 weeks after transduction to generate a stable cell line 
of GAN cells expressing gigaxonin. 
 
TAT-Giga expression, purification, and treatment 
 The GAN cDNA sequence was cloned into the pTAT vector (gift from 
Steve Dowdy, Washington University), which contains an N-terminal 6X His tag 
followed by a transactivator of transcription (TAT) sequence, to generate a 
complete His-TAT-GAN cDNA construct (termed TAT-Giga). The TAT-Giga 
construct was sequenced to ensure fidelity and transformed into 
BL21(DE3)pLysE cells. The transformed cells were grown for 14-16 hours in LB 
broth supplemented with ampicillin (100 µg/mL) at 37°C and then seeded into 
fresh media until the culture reached an optical density of 0.5 at 600 nm. To 
induce the expression of TAT-Giga, 250 µM of IPTG was added, and the culture 
was subsequently incubated at 16°C for four hours. TAT-Giga was then isolated 
and purified using a His-tagged protein purification protocol (250, 251). Briefly, 
the cells were harvested by centrifugation at 4,500 g for 10 minutes at 4°C, 
resuspended in lysis buffer (PBS, pH 7.4, with 500 mM NaCl and Sigma P8849 
protease inhibitor cocktail), and sonicated in a rosette cooling cell. The lysate 
was then clarified by centrifugation at 22,500 g for 20 minutes at 4°C and passed 
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through a 0.75 µm filter. Imidazole was added to the soluble protein lysate to 
reach a final concentration of 10 mM.  
The soluble protein lysate containing the His-tagged TAT-Giga was 
passed over a 5 mL HisTrap FF nickel affinity column (GE Healthcare) using an 
Akta Basic UPC 100 FPLC chromatography system (Amersham Biosciences). To 
elute the His-tagged TAT-Giga protein from the column, the imidazole 
concentration of the elution buffer was gradually increased up to 500 mM. The 
elution fractions with an imidazole concentration from 40-80 mM were collected 
and concentrated using a spin concentrator with a 10,000 MW cutoff (Millipore). 
The concentrated protein was then loaded onto a PD-10 desalting column (GE 
Healthcare) and eluted into PBS with 5% glycerol. The protein concentration of 
the resultant TAT-Giga protein sample was then determined by a BCA assay 
(Thermo Scientific). 
 For treatment with the purified TAT-Giga protein, GAN cells were seeded 
into 35mm dishes containing normal serum media. Sixteen hours later, the cells 
were washed with PBS and then incubated in low serum media (0.1% FBS) 
containing 0.15 µg/mL or 0.75 µg/mL TAT-Giga for the low and high dose 
samples, respectively. PBS was added to the control samples. After 72 hours, 
the cells were isolated and subjected to immunofluorescence or Western blot 
analysis as above. 
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Proteasome inhibition 
Control cells were seeded into 35mm dishes containing normal serum 
media. Sixteen hours later, the cells were washed with PBS and then incubated 
in low serum media (0.1% FBS) with 0.01 µM MG132 (EMD Millipore). After 72 
hours, the cells were isolated and subjected to Western blot analysis as above. 
 
Small interfering RNA (siRNA) inhibition 
Cells were seeded into 35mm dishes containing normal serum media. 
Sixteen hours later, the cells were washed with PBS and incubated in normal 
serum media without penicillin-streptomycin. For all treatments, 50 nM of siRNA 
was diluted in 125 µL of DMEM and 5 µL Lipofectamine 2000 (Life Technologies) 
was diluted in in 125 µL of DMEM. The diluted solutions were mixed together and 
incubated for 20 minutes at room temperature before being added to each well. 
After 6 hours, the media containing the siRNA complexes was removed, the cells 
were washed, and low serum media was added. The cells were grown in low 
serum conditions for 72 hours before being isolated and subjected to Western 
blot or immunofluorescence analysis as above. The siRNAs used were from 
Sigma-Aldrich and included siRNAs targeted against gigaxonin 
(SASI_Hs01_00217960), galectin-1 (SASI_Hs01_00132990), H-Ras 
(SASI_Hs01_00231174), K-Ras (SASI_Hs01_00082296), N-Ras 
(SASI_Hs01_00017654), MEK1 (SASI_Hs01_00090167), and MEK2 
(SASI_Hs01_00109852). 
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Statistics 
Data represent mean ± standard deviation from at least 3 independent 
experiments, with representative blots and images shown. Calculations and 
graphs were compiled using Microsoft Excel. Statistical comparisons were made 
using a 2-tailed Student’s t test, and a P value of 0.05 or less was considered 
significant. 
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CHAPTER III: RESULTS  
 
GAN cells have altered vimentin distribution in low serum 
 GAN patient fibroblasts have a readily inducible phenotype of vimentin 
filament aggregates. When grown in culture conditions containing 10% FBS, 
GAN cells have a mostly normal IF structure, as only 5-10% of GAN cells form a 
vimentin aggregate (84). However, growing the same cells in low serum 
conditions of 0.1% FBS results in the formation of vimentin aggregates in about 
70-80% of GAN cells (82, 84, 85). Although the formation of vimentin aggregates 
is a consistent finding in GAN patient cells, the quantification of such aggregates 
is wildly inconsistent, as the same patient cell line was described as containing 
aggregates in less than 20% of cells in one study (82) and in 90% of the same 
cells in another study (83). This inconsistency cannot be attributed to either 
differences in cell culture or clonal variation between the studies, as the same 
culture conditions were used and there is little clonal variation in GAN cells (82). 
Instead, these discrepancies most likely result from the ambiguous definition of 
an aggregate and how this definition is applied between different studies. Without 
the ability to control for this human error, the phenotypic scoring of aggregates in 
GAN cells cannot be accurately applied as a universal readout of this disease.   
 In conjunction with the phenotypic vimentin aggregates, I found that GAN 
cells also display an abnormal vimentin distribution. Like the formation of the 
aggregates, this distinct phenotype is also inducible by serum restriction. In the 
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permissive growth condition of normal serum (10% FBS), most GAN cells have a 
vimentin structure that is indistinguishable from control cells (Figure 7). However,  
 
 
Figure 7: Vimentin distribution in normal serum (10% FBS) conditions. (A) 
Representative double immunofluorescence of control cells in normal serum with 
an overlay of tubulin (green) and vimentin (red). (B) Single immunofluorescence 
of tubulin in control cells. (C) Single immunofluorescence of vimentin in control 
cells. (D) Representative double immunofluorescence of GAN cells in normal 
serum with an overlay of tubulin (green) and vimentin (red). (E) Tubulin in GAN 
cells. (F) Vimentin in GAN cells. 
 
in the restrictive growth condition of low serum (0.1% FBS), GAN cells display a 
collapsed vimentin network that lacks vimentin in the cell periphery, therefore 
leading to a concentration of vimentin in the perinuclear region (Figure 8D-F). 
48 
 
Control cells do not show a similar phenotype, as their cytoskeletal distribution 
remains unchanged in response to serum conditions (Figure 8A-C). This GAN- 
 
 
Figure 8: Vimentin distribution in low serum (0.1% FBS) conditions. (A) 
Representative double immunofluorescence of control cells in low serum with an 
overlay of tubulin (green) and vimentin (red). (B) Single immunofluorescence of 
tubulin in control cells. (C) Single immunofluorescence of vimentin in control 
cells. (D) Representative double immunofluorescence of GAN cells in low serum 
with an overlay of tubulin (green) and vimentin (red). (E) Tubulin in GAN cells. (F) 
Vimentin in GAN cells. 
 
specific phenotype is observable using tubulin, which is unaltered in GAN cells, 
as a cytoskeletal control for visualization of the total cellular area. Using these 
cytoskeletal markers, I developed a new methodology to describe the GAN 
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phenotype of a retracted vimentin network, which I termed the vimentin free area 
(VFA). The VFA was obtained by using algorithmic thresholding in ImageJ to 
obtain the area of vimentin and tubulin signals (for a detailed methodology please 
see Materials and Methods). As the tubulin structure is unaltered in GAN cells, 
the tubulin area was defined as total cellular area. The vimentin area was then 
divided by the tubulin area to give a ratio of the cellular area that vimentin 
occupies. This vimentin to tubulin ratio was subtracted from one to give the 
cellular area that lacks a vimentin signal, termed the VFA. 
 When quantified, the VFA had similar results to the data obtained by 
previous publications that counted the number of cells with aggregates (84). In 
normal serum conditions, there is no significant difference in the distribution of 
vimentin, as control cells had 10.8% ± 0.9% VFA and the two observed GAN cell 
lines had VFAs of 11.0% ± 2.7% and 8.2% ± 1.1%, respectively (Figure 9). In 
contrast, there was a substantial difference in the VFA in low serum conditions, 
as control cells had 5.2% ± 1.0% VFA whereas both GAN cell lines had 
significantly elevated VFAs of 35.3% ± 1.5% and 20.6% ± 1.0%, respectively. 
These results demonstrate that in addition to the formation of vimentin 
aggregates, GAN fibroblasts also have an altered phenotype of perinuclear 
restricted vimentin distribution as quantified by the VFA. Utilizing this 
computerized scoring of vimentin distribution allows for efficient and reproducible 
quantification of the GAN phenotype while also permitting intermediate nuisances 
in the phenotype that were not accounted for in the previous binary scoring of 
vimentin aggregates. 
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 Figure 9: Quantification of the VFA in normal and low serum. The GAN 
phenotype of a collapsed vimentin network was quantified by the VFA. The VFA 
was then compared between control cells and two distinct GAN cell lines in 
different serum conditions (*P < 0.05 compared to control cells, n=4 replicates 
per condition). 
 
GAN cells have elevated Gal-1 and phosphorylated vimentin in low serum 
 A previous study by Mussche and colleagues (89) utilized differential 
proteomics to demonstrate that GAN cells have increased protein levels of 
galectin-1 (Gal-1) . Here I show that Gal-1 levels are elevated in GAN cells, but 
only significantly in low serum conditions (Figure 10A). Control cells that express 
Giga significantly decreased the amount of Gal-1 when moved from normal to 
low serum, thus indicating a significant down-regulation of Gal-1 in low serum 
conditions (Figure 10B). Conversely, both GAN cell lines tested had no 
detectable levels of Giga and did not display a similar decrease in Gal-1 when 
placed in low serum conditions. When quantified, the GAN cell lines respectively 
had 2.8 and 3.0 times the amount of Gal-1 in low serum when compared to  
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 Figure 10: GAN cells have increased levels of Gal-1 and phosphorylated 
vimentin in low serum. (A) Comparison of protein levels of Gal-1 and 
phosphorylated vimentin at four serine residues in control cells and two distinct 
GAN patient cell lines. Representative blots shown. (B) Quantification of Gal-1 
protein levels in normal and low serum (*P < 0.05 compared to control cells in 
low serum, n=3). (C) Quantification of vimentin protein levels in low serum (*P < 
0.05 compared to control cells, n=3). 
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control cells. These results can be correlated to the observed vimentin 
abnormalities observed in the same GAN fibroblasts, as significant differences in 
Gal-1 protein levels and phenotype are specifically observed in GAN cells when 
compared to controls in low serum. Due to this low serum specific aggravation of 
the GAN phenotype and Gal-1 protein levels, low serum conditions were utilized 
in all further experiments. 
Examination of vimentin protein levels showed no difference in total 
vimentin between control and GAN cells, as previously reported (86, 88, 89). 
However, further assessment using phosphorylation site-specific vimentin 
antibodies showed a general hyperphosphorylation of vimentin in GAN cell lines 
that was specifically observed in low serum (Figure 10C). When quantified, 
vimentin phosphorylation was significantly increased at Ser39 and Ser72 in both 
GAN cell line 1 and GAN cell line 2. The highest increase was at Ser72, as the 
GAN cell lines respectively had 2.9 and 2.3 times the amount of phospho-
vimentin at Ser72 when compared to control cells in low serum. In addition to 
these two sites, GAN cell line 1 also had significantly elevated levels of vimentin 
phosphorylation at both Ser51 and Ser83. With all four tested sites displaying 
increased phosphorylation, GAN cell line 1 displayed consistent vimentin 
hyperphosphorylation and therefore was used as the representative GAN cell line 
in all subsequent experiments. Taken together, these results show a low serum 
specific hyperphosphorylation of vimentin and accumulation of Gal-1 in GAN 
cells that correlates with the altered vimentin structure in the same condition. 
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Giga controls the proteasome mediated degradation of Gal-1 
 As Giga is purported to function as an E3 ligase adaptor, I hypothesized 
that the increased Gal-1 protein levels in GAN cells was caused by the lack of 
Giga-mediated targeting to a protein degradation pathway. To determine the role 
of Giga in the protein degradation of Gal-1, wild-type Giga was replaced in GAN 
cells using two separate techniques. First, the wild-type Giga encoding GAN 
gene was introduced into GAN cells using lentiviral transduction. The transduced 
cells showed high levels of Giga expression and had a corresponding decrease 
of Gal-1 protein levels when compared to the non-transduced GAN cells (Figure 
11). This Giga mediated decrease in Gal-1 was specific, as the levels of other 
probed proteins, including total vimentin, remained unchanged when Giga was 
introduced. Although the total amount of vimentin remained unchanged, the 
levels of vimentin phosphorylation were significantly reduced at Ser39, Ser51, 
Ser72, and Ser83. These results demonstrated that introducing the wild-type 
GAN gene into patient cells decreases the elevated protein levels of Gal-1 and 
reverses vimentin hyperphosphorylation. 
 In addition to replacing the wild-type GAN gene into patient cells, the wild-
type Giga protein was introduced into GAN cells using the transactivator of 
transcription (TAT) cell penetrating peptide. A fusion protein was created with 
wild-type Giga and an N-terminal TAT sequence, which facilitated movement of 
the TAT-Giga fusion protein across the intact cell membrane, thus replacing 
functional Giga into GAN cells. TAT-Giga was administered to two separate GAN 
cell lines, and in both cases, Gal-1 levels decreased when wild-type Giga was 
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 Figure 11: Restoring the wild-type GAN gene decreases Gal-1 and reverses 
vimentin hyperphosphorylation in GAN cells. Wild-type Giga expression was 
introduced into GAN cells via a lentiviral construct. The expression of Gal-1 and 
vimentin phosphorylation at specific serine residues was then compared between 
control cells, GAN cells, and GAN cells transduced with the Giga expressing 
lentiviral vector. All cells were grown in low serum conditions. Representative 
blots shown (n=3). 
 
replaced into the cells (Figure 12). The decrease in Gal-1 was also dose- 
dependent, as the high dose of TAT-Giga (0.75 µg/mL) showed a more profound 
decrease in Gal-1 levels as compared to the low dose of TAT-Giga (0.15 µg/mL). 
Therefore, the levels of Gal-1 can also be decreased upon addition of functional 
Giga to GAN cells, thus demonstrating an inverse relationship between Giga and 
Gal-1 and suggesting Gal-1 as a substrate of Giga. 
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 Figure 12: Replacing wild-type Giga protein into GAN cells decreases Gal-1 
protein levels. Wild-type Giga was replaced into two separate GAN patient cell 
lines via TAT-Giga protein replacement therapy. The expression of Gal-1 and 
total vimentin was then compared between control cells, untreated GAN cells, 
and GAN cells treated with a low dose or high dose of TAT-Giga. All cells were 
grown in low serum conditions. Representative blots shown (n=2). 
 
To further confirm this role, Giga protein expression was knocked down in 
control cells using siRNA. Immunoblotting demonstrated efficient knockdown of 
Giga to undetectable levels, while also showing a corresponding increase of Gal-
1 protein levels that was not seen with a scrambled siRNA control (Figure 13A). 
This result reaffirmed the inverse correlation between the protein levels of Giga 
and Gal-1 that was previously observed in GAN cells, as both control cells 
exposed to Giga siRNA and GAN cells that do not express Giga had significantly 
elevated protein levels of Gal-1. This further confirmation of an inverse 
relationship suggested a possible role for Giga as an E3 substrate adaptor that 
binds to Gal-1 and facilitates its ubiquitination and degradation in the 
proteasome. In support of this relationship, a recent proteomics survey 
demonstrated that Gal-1 is ubiquitinated on 5 distinct lysine residues (252). 
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 Figure 13: Giga controls the proteasome mediated degradation of Gal-1. (A) 
Giga siRNA was added to control cells and grown in low serum conditions. The 
protein levels of Gal-1 were then compared between untreated control cells (Neg 
Cont), control cells administered an siRNA control, control cells treated with Giga 
siRNA, and GAN cells. (B) Proteasome function was inhibited with MG132 in 
control cells and protein levels of Gal-1 were observed over time. 
 
Furthermore, inhibiting the proteasome with MG132 in control cells generated a 
classical poly-ubiquitin ladder and lead to an accumulation of Gal-1 (Figure 13B). 
This suggests that in the presence of Giga, Gal-1 is ubiquitinated and undergoes 
proteasome-mediated degradation. Taken together, these results identify an 
inverse relationship between Giga and Gal-1 that is indicative of a substrate 
adaptor-substrate relationship and also suggests that the Giga mediated 
degradation of Gal-1 occurs in the proteasome. 
 
Restoration of Giga corrects GAN phenotype 
 As mutations in Giga are known to cause intermediate filament 
abnormalities in GAN cells, such as perinuclear vimentin accumulation in 
fibroblasts, I hypothesized that introduction of functional Giga would correct this 
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GAN phenotype. To replace functional Giga, GAN cells were transduced with a 
lentiviral construct that utilized an internal ribosomal entry site to express wild-
type Giga and eGFP from the same mRNA transcript. Triple immunofluorescence 
of tubulin, vimentin, and eGFP showed that those cells expressing eGFP, as a 
marker for the simultaneously expressed Giga, exhibited a normal filamentous 
vimentin distribution throughout the cytoplasm (Figure 14C-D). This was in stark 
contrast to the non-transduced GAN cells, as evident by the lack of eGFP signal, 
which had central vimentin accumulations (Figure 14A-B). When quantified, the 
perinuclear vimentin accumulations of the non-transduced GAN cells resulted in 
35.8% ± 0.8% VFA, while the Giga/eGFP expressing GAN cells had a 
significantly lower VFA of 15.2% ± 1.3% (Figure 14E). This shows that replacing 
Giga in GAN cells can decrease the VFA by restoring vimentin distribution. 
 Similar phenotypic correction was also observed when wild-type Giga was 
administered to GAN cells using TAT-mediated protein replacement therapy. 
After treatment with TAT-Giga, double immunofluorescence studies of vimentin 
and tubulin showed that vimentin distribution was largely restored in GAN cells 
(Figure 15A-C). When compared to untreated GAN cells that showed 
accumulated vimentin in the perinuclear region and are lacking vimentin in the 
cell periphery, the TAT-Giga treated cells displayed a more even distribution of 
vimentin throughout the cellular area that is phenotypically closer to the control 
cells. Quantification of this experiment using the previously characterized 
formation of VFA showed that untreated GAN cells exhibited 32.5% ± 1.7% VFA, 
which decreased in a dose dependent manner to 20.7% ± 0.5% and 11.4% ±  
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 Figure 14: Restoring wild-type GAN gene corrects the GAN phenotype. (A) 
Non-transduced GAN cells stained for tubulin (green) and vimentin (red). (B) 
Lack of eGFP in non-transduced GAN cells. (C) GAN cells transduced with the 
GAN gene and stained for tubulin (green) and vimentin (red). (D) eGFP 
expression in transduced GAN cells. (E) Quantification of the VFA in normal, 
GAN, and transduced GAN cells (*P < 0.05 compared to GAN negative control 
cells, n=4 per condition). All cells were grown in low serum conditions. 
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 1.0% VFA in GAN cells treated with a low dose (0.15 µg/mL) and high dose (0.75 
µg/mL) of TAT-Giga, respectively (Figure 15D). Together, these results 
demonstrate that replacing either the functional Giga protein, or the wild-type 
GAN gene, can restore vimentin distribution in GAN cells. In addition, this data 
validates VFA scoring as a dynamic and correctable phenotypic readout for GAN. 
 
 
Figure 15: Restoring Giga corrects the GAN phenotype. (A) Representative 
tubulin (green) and vimentin (red) overlay image of control cells. (B) Overlay 
image of untreated GAN cells. (C) Overlay of TAT-Giga treated GAN cells. (D) 
Quantification of the VFA in control, GAN, and TAT-Giga treated GAN cells (*P < 
0.05 compared to GAN negative control cells, n=4 per condition). All cells were 
grown in low serum conditions. 
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Gal-1 knockdown decreases vimentin phosphorylation and restores 
vimentin distribution 
 Since restoring Giga expression in GAN cells decreased the elevated 
levels of Gal-1, abated vimentin hyperphosphorylation, and corrected vimentin 
distribution, I hypothesized that directly decreasing Gal-1 levels in GAN cells 
would similarly rectify the GAN phenotype. Addition of a Gal-1 siRNA to GAN 
cells resulted in efficient and specific knockdown of Gal-1, as measured by 
immunoblotting, which was not observed with a scrambled siRNA control (Figure 
16). In conjunction with decreased protein levels of Gal-1, GAN cells treated with  
 
 
Figure 16: Gal-1 knockdown reduces vimentin phosphorylation. Gal-1 
siRNA was administered to GAN cells in low serum conditions. The protein levels 
of specific vimentin phosphorylation sites were then compared between control 
cells, untreated GAN cells (Neg Cont), GAN cells given an siRNA control, and 
GAN cells treated with a Gal-1 siRNA. Representative blots shown (n=3). 
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Gal-1 siRNA also displayed significantly reduced levels of vimentin 
phosphorylation at Ser72 and Ser83 to levels commensurate with those of 
control cells. Phosphorylation at these sites, as noted previously in Figure 10A, is 
elevated in GAN cells and remains elevated when a scrambled siRNA control is 
added to the cells. This data suggests that a specific knockdown of Gal-1 can 
affect the phosphorylation state of vimentin at multiple different serine sites 
without altering the total vimentin protein levels. Furthermore, GAN cells treated 
with Gal-1 siRNA demonstrated increased vimentin distribution to the cell 
periphery and increased colocalization of tubulin and vimentin as measured by 
immunofluorescence (Figure 17A-C). In contrast, addition of the siRNA control 
had no effect on the GAN cell phenotype, as they displayed a collapsed vimentin 
network that lacked vimentin in the cell periphery. Quantification of this data 
showed GAN cells administered the siRNA control had 36.3% ± 1.4% VFA, while 
Gal-1 siRNA treated GAN cells had a significantly lower VFA of 14.7% ± 0.4% 
that was much closer to the 3.9% ± 1.3% VFA observed in control cells (Figure 
17D). Taken together, these results show that a knockdown of Gal-1 decreases 
vimentin phosphorylation, while also showing a corresponding decrease in VFA. 
The increased colocalization observed in Gal-1 knockdown GAN cells not only 
reveals that decreasing the levels of Gal-1 can correct the GAN phenotype, but 
more importantly that Gal-1 accumulation is critical to the formation of GAN. 
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 Figure 17: Gal-1 knockdown corrects vimentin distribution. (A) 
Representative tubulin (green) and vimentin (red) overlay image of control cells. 
(B) Overlay image of siRNA control treated GAN cells. (C) Overlay of Gal-1 
siRNA treated GAN cells. (D) Quantification of the VFA in control cells, siRNA 
control treated GAN cells, and Gal-1 siRNA treated GAN cells (*P < 0.05 
compared to GAN siRNA control cells, n=4 per condition). All cells were grown in 
low serum conditions. 
 
H-Ras siRNA decreases vimentin phosphorylation and improves vimentin 
distribution 
 As the previous data demonstrated the integral role of Gal-1 in the 
formation of GAN, I sought to determine the signaling proteins downstream of 
Gal-1 that were critical to formation of the GAN phenotype. Gal-1 has previously 
been shown to specifically bind to and stabilize H-Ras, while having little to no 
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affinity for the other two Ras isoforms of K-Ras and N-Ras (165). With this data, I 
hypothesized that accumulated Gal-1 signals specifically through H-Ras to 
mediate vimentin hyperphosphorylation and vimentin disorganization in GAN 
cells. To test this, specific siRNAs corresponding to each Ras isoform was added 
to GAN cells individually, and an efficient knockdown was observed for H-Ras, K-
Ras, and N-Ras (Figure 18). Immunoblotting shows increased levels of  
 
 
Figure 18: H-Ras specific knockdown exclusively reduces vimentin 
phosphorylation. Specific Ras isoform siRNA was administered to GAN cells 
grown in low serum conditions. The protein levels of specific vimentin 
phosphorylation sites were then compared between control cells, untreated GAN 
cells (Neg Cont), GAN cells given an siRNA control, and GAN cells treated with a 
Ras isoform siRNA. Representative blots shown (n=3). 
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phosphorylated vimentin in GAN cells, as noted previously, that remain elevated 
with addition of an siRNA control. Upon addition of the siRNA for each Ras 
isoform, only the H-Ras specific siRNA showed a decrease in vimentin 
phosphorylation at Ser51 and Ser83. Conversely, both the K-Ras and N-Ras 
siRNAs had little to no effect on the phosphorylation state of vimentin, as they 
remained unchanged from the GAN cells treated with an siRNA control; 
therefore, K-Ras and N-Ras do not contribute to the increased vimentin 
phosphorylation of GAN cells. Together, these results suggest that accumulated 
Gal-1 signals specifically through the H-Ras isoform to generate the vimentin 
hyperphosphorylation observed in GAN cells. 
 Immunofluorescence was subsequently performed to determine if the H-
Ras specific decrease in vimentin phosphorylation translated into a correction of 
the GAN phenotype. Indeed, only those cells treated with the H-Ras siRNA 
showed increased vimentin distribution and an improved phenotype that more 
resembled the normal cytoskeletal structure of the control cells (Figure 19A-C). 
This phenotypic observation was confirmed by VFA quantification, which showed 
that the 35.2% ± 1.4% VFA area observed for GAN cells with siRNA control was 
significantly decreased to 22.6% ± 0.8% VFA upon addition of H-Ras siRNA 
(Figure 19D). Unlike the H-Ras siRNA, addition of either the K-Ras or the N-Ras 
siRNA had no discernable effect on the GAN phenotype, as both conditions 
resulted in the perinuclear vimentin accumulation that is seen in GAN cells 
transfected with an siRNA control. Upon quantification, GAN cells treated with K- 
Ras and N-Ras siRNAs had VFAs of 31.2% ± 2.2% and 31.0% ± 1.3%, 
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 Figure 19: H-Ras siRNA improves vimentin distribution. (A) Representative 
tubulin (green) and vimentin (red) overlay image of control cells. (B) Overlay 
image of siRNA control treated GAN cells. (C) Overlay of H-Ras siRNA treated 
GAN cells. (D) Quantification of the VFA in control cells, siRNA control treated 
GAN cells, and Ras isoform siRNA treated GAN cells (*P < 0.05 compared to 
GAN siRNA control cells, n=4 per condition). All cells were grown in low serum 
conditions. 
 
respectively, and these values were not significantly different from the 35.2% ± 
1.4% VFA observed in GAN cells with the siRNA control. This data collectively 
demonstrates that only siRNA against the H-Ras specific Ras isoform has the 
ability to decrease vimentin hyperphosphorylation and improve vimentin 
distribution. Therefore, the H-Ras isoform is suggested to be critical to the 
formation of GAN and functions downstream of Gal-1 to cause the 
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hyperphosphorylation of vimentin and the altered vimentin distribution observed 
in GAN cells. 
 
MEK1/2 knockdown reduces vimentin phosphorylation and improves 
vimentin distribution 
 As the previous data demonstrated that the GAN phenotype was 
dependent on H-Ras signaling, I sought to determine the downstream Ras 
effectors that contribute to the formation of GAN. The utilization of Ras effectors 
is altered by Gal-1 such that Ras signaling is diverted to Raf-1 at the expense of 
PI3K, thus leading to activation of the downstream Raf-1 effectors of mitogen-
activated protein kinase kinase 1 and 2 (MEK1 and MEK2). I therefore 
hypothesized that MEK1 and MEK2 contribute to the vimentin 
hyperphosphorylation and vimentin disorganization observed in GAN cells. 
To determine their involvement in GAN, the levels of MEK1 and MEK2 proteins 
were decreased by separate siRNAs that ablated the expression of each protein 
(Figure 20). The decreased protein levels of MEK1 and MEK2 also generated 
reduced levels of vimentin phosphorylation at Ser83, thus demonstrating the 
involvement of MEK1 and MEK2 in the phosphorylation of vimentin at that 
specific site.  
When these cells were observed by immunofluorescence, the combination 
of MEK1/2 siRNAs displayed significantly improved vimentin distribution (Figure 
21A-C). This was reflected in the VFA quantification, as the siRNA control treated 
GAN cells had a VFA of 35.3% ± 0.6%, while the MEK1/2 siRNA treated GAN  
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 Figure 20: MEK1/2 siRNA reduces vimentin phosphorylation at Ser83. 
MEK1 and MEK2 siRNA was administered to GAN cells grown in low serum 
conditions. The protein levels of specific vimentin phosphorylation sites were 
then compared between control cells, untreated GAN cells (Neg Cont), GAN cells 
given an siRNA control, and GAN cells treated with a combination of MEK1/2 
siRNAs. Representative blots shown (n=3). 
 
cells had a VFA of 24.6% ± 0.4% (Figure 21D). Taken together, this data 
demonstrates that MEK1 and MEK2 are critical to the formation of the GAN 
phenotype, as they contribute to the hyperphosphorylation and disorganization of 
vimentin. 
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 Figure 21: MEK1/2 siRNA improves vimentin distribution. (A) Representative 
tubulin (green) and vimentin (red) overlay image of control cells. (B) Overlay 
image of siRNA control treated GAN cells. (C) Overlay of MEK1/2 siRNA treated 
GAN cells. (D) Quantification of the VFA in control cells, siRNA control treated 
GAN cells, and MEK1/2 siRNA treated GAN cells (*P < 0.05 compared to GAN 
siRNA control cells, n=4 per condition). All cells were grown in low serum 
conditions. 
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CHAPTER IV: DISCUSSION 
 
GAN is a progressive neurodegenerative disease that is characterized by 
giant axons filled with disorganized NFs. Although many different 
neurodegenerative diseases display similar NF phenotypes, GAN is unique in 
that seemingly all classes of IFs are affected, as IF abnormalities have been 
noted in the patient hair cells, fibroblasts, myocytes, and additional cell types. 
These systemic IF phenotypes are therefore not attributable to a mutation in one 
class of IF, but rather are caused by a defect in a ubiquitous protein that controls 
cytoskeletal organization. 
 GAN has been linked to autosomal recessive mutations of the GAN gene, 
which codes for the Giga protein. Based on sequence similarity, Giga is predicted 
to function as a substrate adaptor for a multisubunit E3 ubiquitin ligase and loss 
of this function in GAN patients would lead to an accumulation of any substrate. 
However, substrates of Giga have proven difficult to identify and potential 
substrates that have been proposed show no relationship to the observed 
phenotype of IF abnormalities. A recent proteomics study identified five proteins, 
including Gal-1, that were significantly increased in GAN patient cell, thus making 
them potential substrates of Giga (89). 
 Gal-1 functions to stabilize activated Ras and promotes its signaling 
through Raf-1, which then activates multiple protein kinases that are known to 
phosphorylate intermediate filaments. Generally, the phosphorylation of 
intermediate filaments promotes the disassembly of the normal filament 
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structure, leading to a retraction of IFs away from the cell periphery and toward 
the center of the cell. This phenotype is similar to that observed in GAN patient 
cells, which lead us to hypothesize that Giga regulates IF phosphorylation and 
structure by modulating the Ras pathway through the degradation of Gal-1. The 
following section will review the principal results of this study and discuss their 
impact in the context of GAN. 
 
GAN cells have altered vimentin distribution in low serum 
 Without a functional mouse model to study the disease, the fibroblasts of 
GAN patients represent the main modality used to study GAN. These cells can 
be utilized because, like the neurons of the patients, they contain a disorganized 
IF structure. In GAN patient fibroblasts, this disorganization manifests as 
cytoplasmic vimentin aggregates near the nucleus. This distinctive feature has 
previously been used to quantify the vimentin phenotype as a percentage of cells 
containing aggregates. Such methodology, however, has demonstrated limited 
utility due to high variability in the percentages of GAN cells with aggregates 
being reported for the same cell lines (82, 83). These inconsistent findings are 
most likely due to the arbitrary definition of an aggregate and the human error 
involved in making this nuanced decision. 
 Although this aggregate phenotype is the most striking feature of GAN 
cells, the formation of the aggregate is simultaneous accompanied by a retraction 
of vimentin from the periphery. In this study, I developed a new scoring system 
based on this retraction of vimentin from the periphery of GAN cells, which I 
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quantified as the vimentin free area (VFA). This quantification system uses 
automated thresholding based on freely available software to obtain the area of 
vimentin staining in relation to the total cellular area. Utilizing this computerized 
scoring system removes any previous ambiguity to what was defined as an 
aggregate and allows consistent reproducible results that can be produced on 
multiple imaging platforms.  
  This phenotype of an altered vimentin distribution resembles what is 
observed during distinct stages of the cell cycle. In mitosis, a vast rearrangement 
of the IF is observed, which allows the disassembly of the cellular structural 
components and subsequent segregation into the daughter cells. Throughout this 
process, a general vimentin hyperphosphorylation is observed in concert with the 
disassembly of the IF structure. This phosphorylation-induced disassembly is first 
observed in late prophase, when vimentin is retracted from the cellular periphery 
to form a centrosomal vimentin aggregate. As this is a similar phenotype to the 
one observed in GAN, I hypothesized vimentin hyperphosphorylation also causes 
the formation of VFA in GAN patient cells. 
 
GAN cells have elevated Gal-1 and phosphorylated vimentin in low serum 
 The GAN phenotype of induced vimentin retraction and aggregate 
formation in low serum conditions has been well described, but a molecular 
mechanism leading to this serum-based aggravation has not been determined. 
Here, I demonstrated that GAN cells have elevated levels of Gal-1 exclusively in 
low serum conditions, and that this pathway can account for the GAN phenotypic 
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discrepancy based on serum conditions. When grown in low serum, cells are 
synchronized in G0 resting phase and no longer undergo cell division. This 
occurs due to the scarcity of growth factors supplied by the 0.1% FBS 
supplemented into the low serum media. Without these growth factors, there is 
little activation of signaling pathways, such as Ras. For control cells, the low 
protein levels of Gal-1 reinforces the lack of Ras signaling, as there is little Gal-1 
to stabilize any Ras activated by the low basal level of growth factors. Together, 
these conditions generate limited Gal-1 stabilized Ras activation, which leads to 
the decreased vimentin phosphorylation observed in control cells grown in low 
serum. This low level of vimentin phosphorylation allows the control cells to 
maintain the normal vimentin structure and distribution that is required in non-
dividing cells. 
 In contrast, the GAN cells maintain high levels of Gal-1 in the absence of 
Giga when grown in low serum. These elevated levels of Gal-1 allow any amount 
of Ras activated by the low concentration of serum growth factors to be 
maintained in the activated state. This activated Ras can then signal through Raf-
1 to induce vimentin phosphorylation, and this is observed as GAN cells have 
significantly elevated phosphorylated vimentin levels at serine residues 39, 51, 
72, and 83. As seen during the cell cycle, vimentin phosphorylation correlates 
with a retraction of vimentin from the periphery of the cell and the formation of a 
centrosomal aggregate. This phenotype is mirrored in GAN cells. Accordingly, I 
propose that elevated levels of Gal-1 lock Ras in an activated state that leads to 
vimentin hyperphosphorylation in GAN cells grown in low serum. 
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 The serum-based differences in Gal-1 protein levels and vimentin 
phosphorylation are also reflected in the phenotypes of both cell types. For 
control cells, a decrease in VFA is observed that mirrors the decrease of Gal-1 
when they are moved from normal to low serum conditions. This is indicative of 
the cell cycle state of control cells in the two serum condition. In low serum, the 
lack of growth factors coupled with low Gal-1 expression lead to generally low 
levels of vimentin phosphorylation. This allows for the control cells to maintain a 
normal filamentous IF structure that is characteristic of an interphase cell. 
However, in normal serum conditions, a subset of control cell are progressing 
through the cell cycle and therefore will transiently have a retracted vimentin 
network as they progress through prophase. This is reflected in the VFA 
measurement for control cells, as they have increased VFA in normal serum as 
compared to low, thus indicating increased cell cycle activity in normal serum. 
 GAN cells grown in normal serum are indistinguishable from control cells 
when scored by VFA. This is of particular note, as it seems to reflect the similar 
levels of Gal-1 expressed between the two cell lines in these culture conditions. 
When GAN cells are moved into low serum, however, their VFA drastically 
increases and appears to be related to the increased levels of Gal-1 that are 
maintained by GAN cells in this condition. As reflected by their increased VFA in 
low serum, the GAN cells appear to become locked into an IF phenotype that is 
reminiscent of cycling cells in late prophase. This raises the possibility that the 
low serum condition synchronizes control cells in the G0 resting phase, but 
synchronizes GAN cells in prophase. Together, these results demonstrate low 
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serum specific increases in Gal-1 and vimentin phosphorylation in GAN cells that 
can account for the phenotypic differences between GAN and control fibroblasts.  
 
Giga controls the proteasome mediated degradation of Gal-1 
 As a proposed substrate adaptor, Giga should have an inverse 
relationship with a potential substrate, like Gal-1. For example, increasing the 
protein levels of a substrate adaptor should facilitate the proteasome mediated 
degradation of any substrate, leading to decreased protein levels of the 
substrate. This relationship was demonstrated for Giga and Gal-1, as replacing 
wild-type Giga through either lentiviral transduction or protein replacement 
therapy caused a significant decrease in the protein levels of Gal-1. These 
findings suggest that Gal-1 is in fact a substrate of Giga. 
 This inverse relationship was observed in every experiment, with one 
exception arising when comparing normal and low serum protein levels of Giga 
and Gal-1 in control cells. In this experiment Giga is expressed at equivalent 
levels in both growth conditions, but Gal-1 only appears to be degraded in low 
serum. This appears to create a contradiction in normal serum, as Giga is 
expressed but Gal-1 does not appear to be degraded. However, this scenario 
may be explained by the substrate adaptor binding to the substrate being 
regulated by post-translational modifications. Generally, post-translational 
modification of the substrate is a prerequisite for substrate adaptor binding and 
degradation (101, 253). This modification-specific degradation allows for the 
targeting of a specific pool of substrates to be degraded, while also maintaining a 
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basal level of the substrate that is not subjected to degradation. Additionally, 
post-translational modification of the substrate adaptors themselves have also 
been shown to be required for substrate binding in some cases (101). As Giga is 
present in control cells at equivalent levels in both normal and low serum, this 
scenario presents a possible pathway in which Giga and/or Gal-1 are modified 
exclusively in low serum to facilitate their interaction and subsequently induce the 
degradation of Gal-1. 
 
Gal-1 knockdown decreases vimentin phosphorylation and restores 
vimentin distribution 
 Directly decreasing the protein levels of Gal-1 in GAN cells resulted in 
decreased vimentin phosphorylation and also a significant decrease in the VFA 
of these cells. Together these results suggest the direct involvement of Gal-1 in 
the formation of GAN, and such involvement could explain multiple different 
aspects of the disease. First, Gal-1 is widely expressed in most cells, which could 
explain why IF abnormalities are seen in various different GAN cell types (148, 
159). For all cells that express Gal-1, the lack of Giga expression in GAN patients 
could lead to Gal-1 accumulation and aberrant signaling leading to similar IF 
abnormalities seen in patient fibroblasts. Although Gal-1 is expressed in most cell 
types, its expression is the highest in primary sensory and motor neurons of the 
spinal cord and brain stem (157). These sensory and motor neurons also happen 
to be the most affected cells in GAN patients and the neurodegeneration of these 
cells leads to progressive loss of ambulatory ability in patients. The inability to 
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regulate Gal-1 protein levels in these specific cells that inherently have high 
expression levels could generate the particularly high levels of dysfunction 
observed in GAN patient sensory and motor neurons. Additionally, Gal-1 
expression is much lower throughout the brain, which may explain why the brain 
is largely unaffected and allows most patients to maintain normal mentation 
(158). Similar low levels of Gal-1 expression outside the nervous system may 
also justify why other organ system appear to be unaffected in GAN patients. 
 In addition to multiple aspects of GAN being related to the spatial 
expression of Gal-1, the temporal expression of Gal-1 also appears to be related 
to the progression of the disease. The expression of Gal-1 in sensory neurons is 
first detected after neuronal differentiation and Gal-1 levels remain high 
throughout the process of neuronal maturation (158). After synaptogenesis, 
however, Gal-1 is normally observed at much lower levels (158). In humans, the 
process of synaptogenesis occurs throughout the initial stages of development, 
but a peak synapse density occurs during the juvenile period of three to five 
years of age (254). Therefore, synaptogenesis occurs around the time that GAN 
patients initially present with symptomatic gait disturbances. This presents an 
intriguing possibility that Gal-1 is normally involved in the growth and 
development of neurons, but is down-regulated after neuronal maturation. The 
down-regulation of Gal-1 after synaptogenesis could be related to Giga function, 
thus leading to aberrantly high levels of Gal-1 in GAN patients after the normal 
neuronal maturation ends. In this case, the accumulated Gal-1 could then 
facilitate abnormal IF hyperphosphorylation as is seen in GAN patient fibroblasts. 
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H-Ras siRNA decreases vimentin phosphorylation and improves vimentin 
distribution 
 Since Gal-1 siRNA improved the GAN phenotype, I proceeded further 
down the proposed signaling pathway to target the main Gal-1 binding partner: 
Ras. Treatment of GAN cells with siRNA directed against the three Ras isoforms 
demonstrated that only the H-Ras siRNA decreased the vimentin 
hyperphosphorylation and formation of VFA. This result was in agreement with 
previous reports that demonstrated that Gal-1 only bound and stabilized H-Ras 
and had no affinity for K-Ras or N-Ras. Together, these results demonstrate a 
pathway where increased H-Ras signaling, due to Gal-1 stabilization, leads to the 
increased vimentin phosphorylation and VFA in GAN patient cells. 
 A Gal-1 mediated hyperphosphorylation of IFs could explain many aspects 
of the giant axons observed in patients, including the location of the enlarged 
axons in the distal region of the nerve. The phosphorylation of NFs occurs in a 
proximal to distal gradient, with the highest levels of phosphorylation observed in 
the most distal axonal region (206, 255). This distal region of the axon is also 
where the axonal enlargements are concentrated in GAN neurons (18, 82). As 
hyperphosphorylation of NFs has been demonstrated to cause their bundling and 
accumulation, it is possible that the normal cellular machinery responsible for 
phosphorylation is dysfunctional in GAN patients, thus leading to the formation of 
distal neuronal aggregates (244, 247, 248). NF phosphorylation also alters their 
transport by interrupting the association with kinesin, leading to a slower rate of 
anterograde transport (235, 240, 244). With this slowing of anterograde transport, 
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NF phosphorylation has also been shown to lead to distal accumulations of NFs 
(256). Altogether, NF hyperphosphorylation could contribute to the formation of 
distal axonal enlargements by increased NF bundling and interrupted 
anterograde NF transport. 
  
Future directions  
 This thesis research presents a model for the underlying cause of GAN in 
which the loss of Giga leads to an accumulation of Gal-1 and subsequent 
hyperphosphorylation of IFs. Although this study provided multiple lines of 
experimentation concluding that Giga functions as a substrate adaptor to control 
the degradation of Gal-1, I was unable to demonstrate the direct binding required 
to verify this function. This is most likely due to the transient nature of this 
reaction and the inherently low expression levels of Giga. Future studies will 
need to address this binding to solidify Giga as a substrate adaptor that targets 
Gal-1 for degradation. If Giga and Gal-1 binding is verified, additional studies 
should be performed to determine if the Giga and Gal-1 binding is induced by 
post-translational modifications. This idea is suggested by the observation that 
Gal-1 down-regulation occurs in low serum conditions in control cells without an 
increase in Giga protein. The modification of either or both partners could 
specifically facilitate this interaction in low serum conditions, and without the 
signal in normal serum, the binding may not occur.  
After verification of Giga’s function as a substrate adaptor, additional 
binding partners of Giga should be identified. Most substrate adaptors have the 
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ability to bind more than one substrate, so in addition to Gal-1, it is likely Giga 
also controls the degradation of additional proteins. This scenario is supported by 
comparing the western blot results of the lentiviral experiments restoring Giga 
expression to those of the Gal-1 siRNA experiments. When wild-type Giga 
expression was restored with the lentiviral construct, a generalized decrease in 
vimentin phosphorylation was observed in GAN cells. This decrease included all 
four tested vimentin phosphorylation sites at serine residues 39, 51, 72, and 83. 
In contrast, only two vimentin phosphorylation sites were significantly decreased 
with the Gal-1 siRNA. These differences in the vimentin phosphorylation state 
between the two experiments may be attributed to what each treatment 
accomplished. In the first case of the Giga lentivirus, replacing the wild-type 
protein into the GAN cells enabled the functional Giga to facilitate the 
degradation of all potential substrates and lead to reduced vimentin 
phosphorylation at all four tested serine residues. Conversely, treatment with the 
Gal-1 siRNA merely decreased the protein levels of one potential Giga 
substrates and only lead to reduced vimentin phosphorylation at two of the four 
tested serine residues. These results suggest that Gal-1 mediated signaling 
contributes to increased vimentin phosphorylation at two specific residues, but 
other potential Giga substrates may be responsible for the hyperphosphorylation 
of vimentin at addition sites. 
Further evidence of additional Giga substrates was demonstrated by the 
immunofluorescence results of Giga restoration compared to Gal-1 siRNA 
treatment in GAN cells. First, Giga restoration via lentiviral transduction or protein 
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replacement therapy generated treated patient cells that were indistinguishable 
from controls, as they not only had corrected vimentin distribution, but also 
completely lack the vimentin aggregates that are observed in untreated GAN 
cells (data not shown). In contrast, treating the GAN cells with a Gal-1 specific 
siRNA only resulted in corrected vimentin distribution, while having little effect on 
the formation of vimentin aggregates (data not shown). These vimentin 
aggregates clearance with Giga replacement and the persistence of aggregates 
with Gal-1 siRNA suggest that additional Giga substrates, besides Gal-1, may be 
involved in the formation of the aggregates.  
Additional Giga substrates may include the first purported substrates of 
MAP1B, TBCB, and MAP8 (93, 124-126). Although the validity of these three 
MAPs as Giga substrates has been brought into question by previous 
publications (85, 86, 89), my data demonstrates elevated levels of MAP1B and 
TBCB in GAN cells that is suggestive of these proteins being Giga substrates 
(Figure 22). These elevated levels of MAP1B and TBCB are low serum specific 
and follow the same serum based expression pattern as that of Gal-1. In control 
cells, the protein levels of both MAP1B and TBCB are decreased as the cells are 
moved from normal to low serum. In GAN cells, however, no such low serum 
decrease is observed, therefore leading to elevated levels of MAP1B and TBCB. 
Accumulation of MAPs such as MAP1B and TBCB are known to alter the 
microtubule structure and dynamics by promoting the assembly and/or 
disassembly of microtubules (134, 135, 141, 142). GAN cells, however, present a 
phenotypically normal microtubule network that has no apparent direct link to the  
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 Figure 22: Elevated protein levels of MAP1B-LC and TBCB specifically in 
low serum conditions. Comparison of the protein levels of Gal-1, MAP1B, and 
TBCB in control cells and two distinct GAN patient cell lines. Representative blots 
shown (n=3). 
 
abnormal IF structure of patient cells, which has previously led to the dismissal of 
MAP1B and TBCB as being relevant in GAN (82-84). 
 Although the microtubule structure appears to not be directly affected by 
an accumulation of MAP1B and TBCB, increased protein levels of related MAPs, 
such as MAP2, MAP4, or tau, were shown to alter cellular transport by interfering 
with molecular motors (257-259). This interference occurs as the MAPs compete 
with the molecular motors for microtubule binding sides and impede the 
attachment of the motors to the microtubule track (258, 259). The attachment of 
the kinesin motor is preferentially disrupted, thus leading to decreased 
anterograde transport and a subsequent perinuclear accumulation of kinesin 
cargo near the microtubule organizing center (258, 260). Such kinesin cargo 
includes IFs, which form perinuclear IF aggregates when kinesin motility is 
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disrupted by the overexpression of multiple MAPs (258, 260, 261). Therefore, 
while not directly affecting the microtubule structure, the accumulation of MAP1B 
and TBCB could indirectly alter the IF structure by obstructing the movement of 
IF on associated kinesin motors and ultimately result in the formation of 
perinuclear vimentin aggregates that resemble those observed in GAN patient 
fibroblasts. This scenario suggests that the GAN phenotype could occur as a 
consequence of two separate mechanisms resulting from the loss of Giga 
function: the accumulation of MAPs, such as MAP1B and TBCB, leads to the 
formation of perinuclear vimentin aggregates, and/or elevated levels of Gal-1 
cause vimentin phosphorylation and the subsequent retraction of vimentin from 
the cell periphery. Future studies should address whether MAP1B and TBCB are 
Giga substrates and determine their roles not only in the formation of vimentin 
aggregates, but also in the generation of the overall GAN phenotype. 
 Additional insight into the retraction of vimentin from the GAN cell 
periphery was obtained by using an H-Ras specific siRNA, which reduced 
vimentin phosphorylation and improved vimentin distribution in GAN cells. These 
results are highly suggestive of H-Ras contributing to the GAN phenotype, but it 
failed to directly demonstrate increased Ras signaling in GAN. Multiple assays 
were used in attempt to directly address this in GAN cells, but all produced 
inconsistent results using our fibroblast cell models. This result may be due to 
nuances in the cell model and experiment assay that did not fully quantify Ras 
activity, or because of transient nature of the Ras nanoclusters that are formed in 
the presence of Gal-1. Future studies should directly reinvestigate whether there 
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is increased Ras activity in GAN cells and further determine the exact 
downstream pathway in which H-Ras facilitates the formation of GAN. If the Ras 
pathway involvement is confirmed, it would suggest that small molecule inhibitors 
of downstream Ras effectors may prove effective in the treatment of GAN. Taken 
together, this study demonstrates that Giga regulates IF phosphorylation and 
structure by decreasing Ras signaling through the degradation of Gal-1, and 
provides a framework for utilizing Ras pathway inhibitors as a therapy for this 
currently immedicable genetic disease. 
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